<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="hht" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">hht</book-part-id>
      <title-group>
        <title>Hereditary Hemorrhagic Telangiectasia</title>
        <alt-title alt-title-type="alt-title">Synonyms: HHT, Osler-Weber-Rendu Disease</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>McDonald</surname>
            <given-names>Jamie</given-names>
          </name>
          <degrees>MS, CGC</degrees>
          <aff>Co-Director, HHT Clinic<break/>Departments of Radiology and Pathology<break/>University of Utah Medical Center<break/>Salt Lake City, Utah</aff>
          <email>jamie.mcdonald@hsc.utah.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pyeritz</surname>
            <given-names>Reed E</given-names>
          </name>
          <degrees>MD, PhD, FACMG</degrees>
          <aff>Departments of Medicine and Genetics<break/>Perelman School of Medicine at the University of Pennsylvania<break/>Co-Director, HHT Center<break/>Hospital of the University of Pennsylvania<break/>Philadelphia, Pennsylvania</aff>
          <email>reed.pyeritz@uphs.upenn.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>26</day>
          <month>6</month>
          <year>2000</year>
        </date>
        <date date-type="updated">
          <day>2</day>
          <month>2</month>
          <year>2017</year>
        </date>
        <date date-type="revised">
          <day>16</day>
          <month>3</month>
          <year>2004</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="deafness-overview" document-type="chapter">Hereditary Hearing Loss and Deafness Overview</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="hlrcc" document-type="chapter">Hereditary Leiomyomatosis and Renal Cell Cancer</related-object>
      <abstract id="hht.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct connections between arteries and veins. The most common clinical manifestation is spontaneous and recurrent nosebleeds (epistaxis) beginning on average at age 12 years. Telangiectases (small AVMs) are most evident on the lips, tongue, buccal mucosa, face, chest, and fingers. The average age of onset is generally later than epistaxis, but may be during childhood. Large AVMs often cause symptoms when they occur in the lungs, liver, or brain; complications from bleeding or shunting may be sudden and catastrophic. Approximately 25% of individuals with HHT have GI bleeding, which most commonly begins after age 50 years.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of HHT is established in a proband with three or more of the following clinical features: epistaxis, mucocutaneous telangiectases, visceral AVMs, and/or a family history of HHT. Identification of a heterozygous pathogenic variant in <italic toggle="yes">ACVRL1</italic>, <italic toggle="yes">ENG</italic>, <italic toggle="yes">GDF2</italic>, or <italic toggle="yes">SMAD4</italic> establishes the diagnosis if clinical features are inconclusive.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Nosebleeds are treated with humidification, nasal lubricants, hemostatic products, laser ablation, sclerotherapy, nasal closure, and oral or topical medications. GI bleeding is treated with iron replacement therapy and (if needed) endoscopic ablation, surgical resection of bleeding sites, and/or medical therapy. Pulmonary AVMs with a feeding vessel 1 mm or greater in diameter require consideration of occlusion. Cerebral AVMs are treated, when indicated by location or symptoms, by surgery, embolotherapy, and/or stereotactic radiosurgery. Symptomatic hepatic AVMs are managed medically; liver transplantation is recommended for individuals who do not respond to medical therapy and who develop hepatic failure. Women with HHT considering pregnancy are screened and treated for pulmonary and cerebral AVMs; pulmonary AVMs discovered during pregnancy are treated during the second trimester. Iron replacement is preferred for anemia, but transfusion of packed red blood cells may be necessary for symptomatic anemia.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> When pulmonary AVMs are present or suspected, antibiotic prophylaxis for dental and invasive procedures and a filter on intravenous lines to prevent air bubbles from being inadvertently infused is recommended.</p>
          <p><italic toggle="yes">Surveillance:</italic> Annual evaluations for anemia; supine and sitting pulse-oximetry every one to two years during childhood; evaluation for pulmonary AVMs every five years with contrast echocardiography by age ten years; head MRI in infancy and then rescreening for cerebral AVMs by brain MRI after puberty; periodic screening for gastrointestinal polyps and malignant change in persons with juvenile polyps.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Vigorous nose blowing; lifting heavy objects; straining during bowel movements; electric or chemical cautery for nosebleeds; anticoagulant and anti-inflammatory agents (including aspirin) in individuals with significant nose or GI bleeding; scuba diving unless contrast echocardiography within the last five years was negative for evidence of a right to left shunt; liver biopsy.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Molecular genetic testing is offered to at-risk family members if the germline pathogenic variant has been identified in the family. If the pathogenic variant in the family is not known, at-risk family members should be evaluated for signs and symptoms of HHT and screening should be offered to at-risk family members if the diagnosis cannot be ruled out.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>HHT is inherited in an autosomal dominant manner with considerable intrafamilial variability. Most individuals have an affected parent. Each child of a proband and the sibs of most probands are at a 50% risk of inheriting the pathogenic variant. Prenatal testing is possible for pregnancies at increased risk if the pathogenic variant in the family is known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="hht.Diagnosis">
        <title>Diagnosis</title>
        <sec id="hht.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Hereditary hemorrhagic telangiectasia (HHT) <bold>should be considered</bold> in an individual with any of the following features:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Nosebleeds (epistaxis).</bold> Spontaneous and recurrent; night-time nosebleeds heighten the concern for HHT.</p>
            </list-item>
            <list-item>
              <p><bold>Mucocutaneous telangiectases</bold> (small blanchable red spots that are focal dilatations of post-capillary venules or delicate, lacy red vessels composed of markedly dilated and convoluted venules). Multiple, at characteristic sites, including lips, oral cavity, fingers, and nose. Transillumination of the digits is helpful for detecting vascular lesions not evident on the skin [<xref ref-type="bibr" rid="hht.REF.mohler.2009.356">Mohler et al 2009</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Visceral arteriovenous malformation (AVM).</bold> An arteriovenous malformation lacks capillaries and consists of direct connections between arteries and veins. AVMs may be pulmonary, cerebral, hepatic, spinal, gastrointestinal, or pancreatic.</p>
            </list-item>
            <list-item>
              <p><bold>Family history.</bold> A first-degree relative in whom HHT has been diagnosed</p>
            </list-item>
          </list>
        </sec>
        <sec id="hht.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>According to published consensus clinical diagnostic criteria, the diagnosis of HHT is considered &#x0201c;confirmed&#x0201d; in an individual with <bold>three or more</bold> of the <xref ref-type="sec" rid="hht.Suggestive_Findings">above features</xref>. The diagnosis of HHT is considered &#x0201c;suspected&#x0201d; in an individual with <bold>two</bold> of the above features [<xref ref-type="bibr" rid="hht.REF.shovlin.2000.66">Shovlin et al 2000</xref>]. Identification of a heterozygous pathogenic variant in one of the genes listed in <xref ref-type="table" rid="hht.T.molecular_genetic_testing_used_in">Table 1</xref> establishes the diagnosis if clinical features are inconclusive.</p>
          <p>Note: The application of these clinical diagnostic criteria to children at risk for HHT can be misleading. Symptoms and signs of HHT generally develop during childhood and adolescence; epistaxis, telangiectases, and symptoms of visceral AVMs are frequently absent in affected children (see <xref ref-type="sec" rid="hht.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref>).</p>
          <p>Molecular genetic testing approaches can include <bold>serial single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive</bold>
<bold>genomic testing</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Serial single-gene testing</bold> can be considered. Sequence analysis of <italic toggle="yes">ACVRL1</italic> and <italic toggle="yes">ENG</italic> can be performed first. Deletion/duplication analysis of <italic toggle="yes">ACVRL1</italic> and <italic toggle="yes">ENG</italic> can be done next if no pathogenic variant is found.</p>
              <list list-type="bullet">
                <list-item>
                  <p>Sequence analysis of <italic toggle="yes">SMAD4</italic> should be considered first in any person with HHT and intestinal polyps. <italic toggle="yes">SMAD4</italic> sequence analysis should also be considered in symptomatic individuals in whom no pathogenic variant is identified through sequence analysis and deletion/duplication analysis of <italic toggle="yes">ACVRL1</italic> and <italic toggle="yes">ENG</italic>.</p>
                </list-item>
                <list-item>
                  <p>Sequence analysis of <italic toggle="yes">GDF2</italic> could be considered for symptomatic individuals in whom no pathogenic variant is identified in <italic toggle="yes">ACVRL1, ENG</italic>, or <italic toggle="yes">SMAD4</italic> particularly if dermal telangiectases appear larger than pinhead-pinpoint size and are not limited to the hands, mouth, and face.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">ACVRL1</italic>, <italic toggle="yes">ENG, GDF2, SMAD4</italic> and other genes of interest (see <xref ref-type="sec" rid="hht.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included and the sensitivity of multi-gene panels vary by laboratory and over time. (2) Some multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; thus, clinicians need to determine which multi-gene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost while limiting secondary findings. (3) Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-sequencing based tests.</p>
              <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
            </list-item>
            <list-item>
              <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing and genome sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel that includes the genes in listed in <xref ref-type="table" rid="hht.T.molecular_genetic_testing_used_in">Table 1</xref>) fails to confirm a diagnosis in an individual with features of HHT. Such testing may provide or suggest a diagnosis not previously considered (e.g., mutation of a different gene or genes that results in a similar clinical presentation). For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="hht.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Hereditary Hemorrhagic Telangiectasia</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2">Proportion of HHT Attributed to Pathogenic Variants in This Gene</th>
                  <th id="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
                <tr>
                  <th headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Sequence analysis&#x000a0;<sup>3</sup></th>
                  <th headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>4</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">ACVRL1</italic>
                  </td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">25%-57%&#x000a0;<sup>5,&#x000a0;6</sup></td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">90%&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">10%&#x000a0;<sup>7</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">ENG</italic>
                  </td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">39%-59%&#x000a0;<sup>5,&#x000a0;6</sup></td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">90%&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">10%&#x000a0;<sup>7</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">GDF2</italic>
                  </td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">3 individuals&#x000a0;<sup>8</sup></td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">~100%</td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>9</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">SMAD4</italic>
                  </td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1%-2% <sup>6,&#x000a0;10</sup></td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;99%&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>9</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown&#x000a0;<sup>11,&#x000a0;12</sup></td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">NA</td>
                  <td headers="hd_h_hht.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_1 hd_h_hht.T.molecular_genetic_testing_used_in_1_1_2_2" valign="middle" colspan="2" align="left" rowspan="1">NA</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="hht.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="hht" object-id="hht.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="hht.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="hht.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="hht.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="hht.TF.1.4">
                <label>4. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications</p>
              </fn>
              <fn id="hht.TF.1.5">
                <label>5. </label>
                <p>There is a slight preponderance of <italic toggle="yes">ENG</italic> pathogenic variants in North America (~50%) and in northern Europe [<xref ref-type="bibr" rid="hht.REF.brusgaard.2004.556">Brusgaard et al 2004</xref>, <xref ref-type="bibr" rid="hht.REF.letteboer.2005.8">Letteboer et al 2005</xref>, <xref ref-type="bibr" rid="hht.REF.schulte.2005.595">Schulte et al 2005</xref>, <xref ref-type="bibr" rid="hht.REF.bossler.2006.667">Bossler et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.prigoda.2006.722">Prigoda et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.gedge.2007.258">Gedge et al 2007</xref>] compared to <italic toggle="yes">ACVRL1</italic> pathogenic variants (~35%), and a greater preponderance of <italic toggle="yes">ACVRL1</italic> pathogenic variants in southern Europe [<xref ref-type="bibr" rid="hht.REF.lenato.2006.213">Lenato et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.lesca.2006.598">Lesca et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.olivieri.2007.820">Olivieri et al 2007</xref>].</p>
              </fn>
              <fn id="hht.TF.1.6">
                <label>6. </label>
                <p>Sequence analysis of <italic toggle="yes">ACVRL1, ENG</italic>, and <italic toggle="yes">SMAD4</italic> identifies pathogenic variants in approximately 75% of individuals with HHT [<xref ref-type="bibr" rid="hht.REF.bossler.2006.667">Bossler et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.prigoda.2006.722">Prigoda et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.gedge.2007.258">Gedge et al 2007</xref>, <xref ref-type="bibr" rid="hht.REF.richardsyutz.2010.61">Richards-Yutz et al 2010</xref>]. There are no common pathogenic variants, and sequence variants interpreted to be of uncertain significance are particularly common.</p>
              </fn>
              <fn id="hht.TF.1.7">
                <label>7. </label>
                <p>The use of deletion/duplication analysis in addition to sequence analysis increases the detection rate by approximately 10% for <italic toggle="yes">ACVRL1</italic>- and <italic toggle="yes">ENG</italic>-related HHT [<xref ref-type="bibr" rid="hht.REF.bossler.2006.667">Bossler et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.prigoda.2006.722">Prigoda et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.mcdonald.2011b.335">McDonald et al 2011b</xref>].</p>
              </fn>
              <fn id="hht.TF.1.8">
                <label>8. </label>
                <p>Pathogenic variants in <italic toggle="yes">GDF2</italic> were identified in three individuals with features of HHT [<xref ref-type="bibr" rid="hht.REF.wooderchakdonahue.2013.530">Wooderchak-Donahue et al 2013</xref>].</p>
              </fn>
              <fn id="hht.TF.1.9">
                <label>9. </label>
                <p>No data on detection rate of gene-targeted deletion/duplication analysis are available; however, one large deletion has been associated with juvenile polyposis and HHT [<xref ref-type="bibr" rid="hht.REF.wain.2014.588">Wain et al 2014</xref>].</p>
              </fn>
              <fn id="hht.TF.1.10">
                <label>10. </label>
                <p>Approximately 10% of those who test negative for a pathogenic variant in <italic toggle="yes">ACVRL1</italic> and <italic toggle="yes">ENG</italic> [<xref ref-type="bibr" rid="hht.REF.gallione.2006.793">Gallione et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.lesca.2006.598">Lesca et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.prigoda.2006.722">Prigoda et al 2006</xref>]</p>
              </fn>
              <fn id="hht.TF.1.11">
                <label>11. </label>
                <p>One individual with signs of HHT and prominent pulmonary hypertension had a pathogenic variant in <italic toggle="yes">BMPR2</italic> [<xref ref-type="bibr" rid="hht.REF.rigelsky.2008.2551">Rigelsky et al 2008</xref>].</p>
              </fn>
              <fn id="hht.TF.1.12">
                <label>12. </label>
                <p>Linkage analysis in one pedigree suggests a 5.4-cm disease gene interval on chromosome 5 (HHT3) [<xref ref-type="bibr" rid="hht.REF.cole.2005.577">Cole et al 2005</xref>]. Linkage analysis in another pedigree suggests a disease gene in a 7-Mb region on the short arm of chromosome 7 (7p14) (HHT4) [<xref ref-type="bibr" rid="hht.REF.bayraktoydemir.2006a.2155">Bayrak-Toydemir et al 2006a</xref>]. Rare pedigrees are not linked to any of these loci, suggesting additional heterogeneity.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="hht.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="hht.Clinical_Description">
          <title>Clinical Description</title>
          <p>Hereditary hemorrhagic telangiectasia (HHT) is characterized by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries and result in direct connections between arteries and veins. Small arteriovenous malformations are called telangiectases. The term AVM usually refers to the "large" telangiectases, greater than a few millimeters in diameter and sometimes up to several centimeters in diameter. The most common feature that brings individuals with HHT to medical attention are epistaxis (nosebleeds).</p>
          <p><bold>Epistaxis (nosebleeds).</bold> The nasal mucosa is fragile and minor insults from drying air and repeated minor abrasions result in recurrent bleeding. Epistaxis has an average age of onset of approximately 12 years [<xref ref-type="bibr" rid="hht.REF.aassar.1991.977">Aassar et al 1991</xref>]. As many as 95% of affected individuals eventually experience recurrent epistaxis, with one third having onset by age ten years, approximately 80% by age 20 years, and 90% before age 30 years [<xref ref-type="bibr" rid="hht.REF.berg.2003.585">Berg et al 2003</xref>]. However, many do not have nosebleeds that are frequent or severe enough to cause anemia or to result in medical treatment or consultation. Epistaxis was a common cause of death in HHT before the development of blood transfusion.</p>
          <p><bold>Telangiectases</bold> associated with HHT are found primarily on the lips, tongue, buccal mucosa, face, chest, and fingers. The average age of onset is generally later than epistaxis, but may be during childhood; 30% of affected individuals report telangiectases first appearing before age 20 years and two thirds before age 40 years [<xref ref-type="bibr" rid="hht.REF.berg.2003.585">Berg et al 2003</xref>]. They may appear as pinhead-size lesions or as larger, even raised lesions with multiple draining venules. Telangiectases are distinguished from petechiae and angiomata by their ability to blanch with gentle pressure, and then immediately but often slowly refill. Because of their thin walls, narrow tortuous paths, and proximity to the surface of the skin or to a mucous membrane, telangiectases can rupture and bleed after only slight trauma. Since the contractile elements in the vessel wall are lacking, given the abnormal arterial connection, bleeding from telangiectases is frequently brisk and difficult to stop. Telangiectases of the skin are significantly less likely to bleed than those of the nasal mucosa.</p>
          <p>Telangiectases are common in adulthood throughout the gastrointestinal (GI) mucosa, but most commonly, the stomach and the proximal small intestine (duodenum) are involved. Approximately one quarter of all individuals with HHT eventually have bleeding from GI telangiectases. It most commonly begins after age 50 years, and is slow but persistent; but can become increasingly severe with age [<xref ref-type="bibr" rid="hht.REF.plauchu.1989.291">Plauchu et al 1989</xref>, <xref ref-type="bibr" rid="hht.REF.kjeldsen.2000.415">Kjeldsen &#x00026; Kjeldsen 2000</xref>]. It presents more often as iron deficiency anemia than acute GI hemorrhage; but GI bleeding is a less common cause of iron deficiency in individuals with HHT than under-recognized epistaxis. No particular foods, activities, or medications have been identified as contributors to GI bleeding in individuals with HHT.</p>
          <p><bold>AVMs.</bold> AVMs occur most commonly in the lungs, liver, and brain. Although hemorrhage is often the presenting symptom of cerebral AVMs, most visceral AVMs present as a consequence of blood shunting through the abnormal vessel and bypassing the capillary bed.</p>
          <p>Pulmonary AVMs occur in approximately 30%-50% of affected individuals [<xref ref-type="bibr" rid="hht.REF.mcdonald.2011a.607">McDonald et al 2011a</xref>] and can develop over time but rarely after age 30. Shunting of air, thrombi, and bacteria through pulmonary AVMs (thus bypassing the filtering capabilities of the lungs) may cause transient ischemic attacks (TIAs), embolic stroke, and cerebral and other abscesses. In one series, serious neurologic events including TIA, stroke, and brain abscess occurred in 30%-40% of individuals with pulmonary AVMs with feeding arteries 3.0 mm or greater in diameter [<xref ref-type="bibr" rid="hht.REF.white.1996.2627">White 1996</xref>]. These neurologic complications may occur in individuals with isolated pulmonary AVMs and near-normal arterial oxygen tension. Pulmonary AVMs frequently enlarge with time [<xref ref-type="bibr" rid="hht.REF.white.1996.2627">White 1996</xref>]. One study of 42 children with pulmonary AVMs demonstrated that children can have life-threatening complications from these lesions. More than half presented with exercise intolerance, cyanosis, or clubbing, and although the neurologic complications were less frequent than in adults, they had occurred in 19% prior to detection and treatment [<xref ref-type="bibr" rid="hht.REF.faughnan.2004.826">Faughnan et al 2004</xref>]. Migraine headache and polycythemia are additional complications of pulmonary AVMs. Occasionally, a pulmonary AVM can rupture, leading to hemoptysis.</p>
          <p>The frequency of hepatic vascular abnormalities was 74% in one study that systematically imaged the liver of affected individuals using CT [<xref ref-type="bibr" rid="hht.REF.ianora.2004.250">Ianora et al 2004</xref>] and 41% in another study using ultrasound examination [<xref ref-type="bibr" rid="hht.REF.buscarini.2004a.348">Buscarini et al 2004a</xref>]. However, only a small minority (8% in the study using CT) were symptomatic. Hepatic AVMs can present as high-output heart failure, portal hypertension, or biliary disease [<xref ref-type="bibr" rid="hht.REF.garciatsao.2000.931">Garcia-Tsao et al 2000</xref>]. Hepatic focal nodular hyperplasia is also associated with the shunting effects of blood through these high-flow vascular lesions [<xref ref-type="bibr" rid="hht.REF.buscarini.2004b.1089">Buscarini et al 2004b</xref>, <xref ref-type="bibr" rid="hht.REF.brenard.2010.1253">Brenard et al 2010</xref>].</p>
          <p>In the brain, AVMs are typically present at birth. Cerebral AVMs occur in approximately 10% of individuals with HHT [<xref ref-type="bibr" rid="hht.REF.mcdonald.2011a.607">McDonald et al 2011a</xref>].</p>
          <p>Spinal AVMs appear to be significantly less common, but may present with paralysis.</p>
          <p>Vascular lesions in the pancreas are common but rarely a clinical issue [<xref ref-type="bibr" rid="hht.REF.lacout.2010.479">Lacout et al 2010</xref>].</p>
          <p><bold>Anemia.</bold> Epistaxis, or less commonly GI bleeding, can cause mild to severe anemia, often requiring iron replacement therapy or rarely, blood transfusion. In middle age adults, GI bleeding becomes a more important contributor to anemia and iron deficiency.</p>
          <p><bold>Pulmonary hypertension</bold> is another pulmonary vascular manifestation of HHT. Although much less common than pulmonary AVMs, it can either result from systemic arteriovenous shunting in the liver increasing cardiac output or be clinically and histologically indistinguishable from idiopathic pulmonary arterial hypertension [<xref ref-type="bibr" rid="hht.REF.cottin.2007.361">Cottin et al 2007</xref>, <xref ref-type="bibr" rid="hht.REF.girerd.2010.851">Girerd et al 2010</xref>, <xref ref-type="bibr" rid="hht.REF.austin.2013">Austin et al 2013</xref>] (see <related-object link-type="booklink" source-id="gene" document-id="pph" document-type="chapter">Pulmonary Arterial Hypertension</related-object>).</p>
        </sec>
        <sec id="hht.Phenotype_Correlations_by_Gene">
          <title>Phenotype Correlations by Gene</title>
          <p>Pulmonary AVMs are more common in individuals with <italic toggle="yes">ENG</italic> pathogenic variants, and hepatic AVMs are more common in individuals with <italic toggle="yes">ACVRL1</italic> pathogenic variants. However, both types are clearly multisystem vascular dysplasias with most manifestations described in both [<xref ref-type="bibr" rid="hht.REF.kjeldsen.2005.349">Kjeldsen et al 2005</xref>, <xref ref-type="bibr" rid="hht.REF.bayraktoydemir.2006b.463">Bayrak-Toydemir et al 2006b</xref>, <xref ref-type="bibr" rid="hht.REF.letteboer.2006.371">Letteboer et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.lesca.2007.14">Lesca et al 2007</xref>].</p>
          <p>Pulmonary hypertension in the absence of severe vascular shunting, a rare HHT manifestation, has occurred most commonly in individuals with pathogenic variants in <italic toggle="yes">ACVRL1,</italic> but has also been reported in individuals with pathogenic variants in <italic toggle="yes">ENG</italic> [<xref ref-type="bibr" rid="hht.REF.soubrier.2013.d13">Soubrier et al 2013</xref>].</p>
          <p>Pathogenic variants in <italic toggle="yes">SMAD4</italic> have been reported in families with a combined syndrome of JPS and HHT [<xref ref-type="bibr" rid="hht.REF.gallione.2004.852">Gallione et al 2004</xref>], as well as in families reported to have <related-object link-type="booklink" source-id="gene" document-id="jps" document-type="chapter">JPS</related-object> or HHT only. A recent study found that the majority of families with an <italic toggle="yes">SMAD4</italic> pathogenic variant who had presented as JP only were found to have features of HHT when specifically reexamined for such manifestations [<xref ref-type="bibr" rid="hht.REF.omalley.2012.886">O'Malley et al 2012</xref>].</p>
        </sec>
        <sec id="hht.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Data suggest that no absolute genotype-phenotype correlations exist between clinical phenotypes and specific pathogenic variants [<xref ref-type="bibr" rid="hht.REF.mcdonald.2015.1">McDonald et al 2015</xref>].</p>
        </sec>
        <sec id="hht.Penetrance">
          <title>Penetrance</title>
          <p>HHT displays age-related penetrance with increased manifestations developing over a lifetime.</p>
          <list list-type="bullet">
            <list-item>
              <p>Approximately 50% of diagnosed individuals report having nosebleeds by age ten years and 80%-90% by age 21 years. As many as 95% eventually develop recurrent epistaxis.</p>
            </list-item>
            <list-item>
              <p>The percentage of individuals with telangiectases of the hands, face, and oral cavity is similar to the percentage with epistaxis, but the age of onset of telangiectases is generally five to 30 years later than for epistaxis [<xref ref-type="bibr" rid="hht.REF.plauchu.1989.291">Plauchu et al 1989</xref>, <xref ref-type="bibr" rid="hht.REF.porteous.1992.527">Porteous et al 1992</xref>].</p>
            </list-item>
            <list-item>
              <p>Cerebral AVMs are almost always congenital [<xref ref-type="bibr" rid="hht.REF.faughnan.2011.73">Faughnan et al 2011</xref>]. Intracranial hemorrhage secondary to AVM can be the presenting symptom of HHT in infants and children with HHT [<xref ref-type="bibr" rid="hht.REF.morgan.2002.e12">Morgan et al 2002</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="hht.Anticipation">
          <title>Anticipation</title>
          <p>While intrafamilial variability is considerable, there has been no systematic generational progression to suggest anticipation.</p>
        </sec>
        <sec id="hht.Nomenclature">
          <title>Nomenclature</title>
          <p>The original description of the syndrome was made by Sutton in 1864. However, Osler in the USA, Parkes Weber in the UK, and Rendu in France are typically given credit; hence the eponymous Osler-Weber-Rendu syndrome (or Rendu-Osler-Weber in articles in the French literature). The designation &#x0201c;hereditary hemorrhagic telangiectasia&#x0201d; was suggested in 1912 by one of Osler's residents.</p>
          <p>The gene now identified as <italic toggle="yes">ACVRL1</italic> is referred to in many publications as <italic toggle="yes">ALK1</italic>. Note: Other genes were also previously named <italic toggle="yes">ALK1</italic>.</p>
        </sec>
        <sec id="hht.Prevalence">
          <title>Prevalence</title>
          <p>A number of studies indicate that HHT is significantly more frequent than formerly thought, at least in the populations investigated. The overall incidence of HHT in North America is estimated at 1:10,000 [<xref ref-type="bibr" rid="hht.REF.marchuk.1998.269">Marchuk et al 1998</xref>]; however, this is likely an underestimate [<xref ref-type="bibr" rid="hht.REF.guttmacher.2013">Guttmacher et al 2013</xref>]. For example, when a proband is diagnosed, it is not unusual to identify multiple relatives in the family who have not been diagnosed with HHT but have experienced epistaxis, embolic stroke, or GI bleeding.</p>
          <p>HHT occurs with wide ethnic and geographic distribution. The condition is especially prevalent in the Netherland Antilles because of a founder effect.</p>
        </sec>
      </sec>
      <sec id="hht.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold><italic toggle="yes">ACVRL1</italic>.</bold> Pathogenic variants in <italic toggle="yes">ACVRL1</italic> are a rare cause of pulmonary arterial hypertension [<xref ref-type="bibr" rid="hht.REF.austin.2013">Austin et al 2013</xref>].</p>
        <p><bold><italic toggle="yes">ENG</italic>.</bold> No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">ENG</italic>.</p>
        <p><bold><italic toggle="yes">GDF2</italic>.</bold> No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants in <italic toggle="yes">GDF2</italic>.</p>
        <p><bold><italic toggle="yes">SMAD4</italic>.</bold> Pathogenic variants in <italic toggle="yes">SMAD4</italic> have been reported in families with a combined syndrome of <related-object link-type="booklink" source-id="gene" document-id="jps" document-type="chapter">juvenile polyposis syndrome</related-object> (JPS) and HHT [<xref ref-type="bibr" rid="hht.REF.gallione.2004.852">Gallione et al 2004</xref>], as well as in families who presented with JPS or HHT only [<xref ref-type="bibr" rid="hht.REF.howe.2004.484">Howe et al 2004</xref>, <xref ref-type="bibr" rid="hht.REF.gallione.2006.793">Gallione et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.prigoda.2006.722">Prigoda et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.gallione.2010.333">Gallione et al 2010</xref>]. One study found <italic toggle="yes">SMAD4</italic> pathogenic variants in three of 30 persons referred for DNA-based testing for HHT in whom a pathogenic variant in <italic toggle="yes">ACVRL1</italic> or <italic toggle="yes">ENG</italic> had not been identified [<xref ref-type="bibr" rid="hht.REF.gallione.2006.793">Gallione et al 2006</xref>]. Another study showed that 2% of 194 persons referred for DNA-based testing for HHT had <italic toggle="yes">SMAD4</italic> pathogenic variants [<xref ref-type="bibr" rid="hht.REF.prigoda.2006.722">Prigoda et al 2006</xref>]. Although the proportion of individuals with a pathogenic variant in <italic toggle="yes">SMAD4</italic> who manifest HHT only is unknown, it is suspected that all pathogenic variants in <italic toggle="yes">SMAD4</italic> put individuals and families at risk for manifestations of both JPS and HHT [<xref ref-type="bibr" rid="hht.REF.gallione.2010.333">Gallione et al 2010</xref>]. Reports to date suggesting that the majority of individuals with <italic toggle="yes">SMAD4</italic> pathogenic variants have only JPS are likely attributable to variable expressivity, age-related penetrance of HHT, and clinical evaluation that did not focus on manifestations of HHT [<xref ref-type="bibr" rid="hht.REF.omalley.2012.886">O'Malley et al 2012</xref>]</p>
      </sec>
      <sec id="hht.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Telangiectases and epistaxis can be seen in otherwise healthy individuals.</p>
        <p><bold>Recurrent epistaxis</bold> can be a sign of various bleeding diatheses, including <related-object link-type="booklink" source-id="gene" document-id="von-willebrand" document-type="chapter">von Willebrand disease</related-object>.</p>
        <p><bold>Telangiectases</bold> occur in a number of conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="ataxia-telangiectas" document-type="chapter">Ataxia-telangiectasia</related-object>, characterized by progressive cerebellar ataxia beginning between age one and four years, oculomotor apraxia, frequent infections, choreoathetosis, telangiectases of the conjunctivae, immunodeficiency, and an increased risk for malignancy, particularly leukemia and lymphoma. Diagnosis relies on clinical findings (including slurred speech, truncal ataxia, and oculomotor apraxia), family history, and neuroimaging. Pathogenic variants in <italic toggle="yes">ATM</italic> are causative; inheritance is autosomal recessive.</p>
          </list-item>
          <list-item>
            <p>CRST (<italic toggle="yes">c</italic>alcinosis, <italic toggle="yes">R</italic>aynaud phenomenon, <italic toggle="yes">s</italic>clerodactyly, <italic toggle="yes">t</italic>elangiectasia) syndrome (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/181750">181750</ext-link>)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="rasa1-rel-dis" document-type="chapter">Capillary malformation-arteriovenous malformation</related-object> (CM-AVM) caused in some affected individuals by pathogenic variants in <italic toggle="yes">RASA1. RASA1</italic>-related disorders are characterized by the presence of multiple, small (1-2 cm in diameter) capillary malformations mostly localized on the face and limbs. About 30% of affected individuals also have associated arteriovenous malformations (AVMs) and/or arteriovenous fistulas (AFVs), fast-flow vascular anomalies that typically arise in the skin, muscle, bone, spine, and brain. In persons with <italic toggle="yes">RASA1</italic>-related disorders cutaneous zones of numerous pinpoint telangiectases &#x02013; each surrounded by a white pale halo and typically distributed on the limbs or trunk &#x02013; have also been described [<xref ref-type="bibr" rid="hht.REF.revencu.2013a.1632">Revencu et al 2013a</xref>]. This distribution of telangiectases and the presence of &#x0201c;halos&#x0201d; surrounding each red spot is not typical of HHT. Several individuals with a <italic toggle="yes">RASA1</italic> pathogenic variant have the clinical diagnosis of Parkes Weber syndrome (multiple micro-AVFs associated with a cutaneous capillary stain and excessive soft tissue and skeletal growth of an affected limb).</p>
          </list-item>
          <list-item>
            <p>Hereditary benign telangiectasia (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/187260">187260</ext-link>), characterized by widespread telangiectases, predominantly on the face, upper limbs, and upper trunk. The telangiectases are venular and associated with upper dermal atrophy. It should be suspected in persons without a history/family history of nosebleed or other bleeding, mucosal telangiectases, AVM, or characteristic pattern of telangiectasia distribution found in HHT.</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
          <list-item>
            <p>Chronic liver disease (However, the telangiectases are almost always of the 'spider' class and occur on the face and chest and around the umbilicus.)</p>
          </list-item>
        </list>
        <p>Additionally, adults can develop one or a couple of cutaneous telangiectases with age. These often raise concern, especially when the person also has multiple cherry angiomata, which are quite frequent in older individuals and are unrelated to HHT.</p>
        <p><bold>Pulmonary AVMs.</bold> Most individuals with a pulmonary AVM have HHT; an unknown percentage of individuals who have an isolated pulmonary AVM do not have HHT.</p>
        <p><bold>Cerebral AVMs</bold> occur most frequently as an isolated finding, but may be a manifestation of HHT or another dominantly inherited vascular dysplasia such as <related-object link-type="booklink" source-id="gene" document-id="rasa1-rel-dis" document-type="chapter">capillary malformation-arteriovenous malformation</related-object> (CM-AVM) caused by pathogenic variants in <italic toggle="yes">RASA1</italic> [<xref ref-type="bibr" rid="hht.REF.eerola.2003.1240">Eerola et al 2003</xref>, <xref ref-type="bibr" rid="hht.REF.revencu.b">Revencu et al 2013b</xref>]. Families have also been reported with autosomal dominant AVMs of the brain and no other features of HHT. However, the presence of multiple cerebral AVMs is highly suggestive of HHT [<xref ref-type="bibr" rid="hht.REF.bharatha.2012.72">Bharatha et al 2012</xref>]. The absence of a family history of recurrent nosebleed and presence of telangiectases specifically on the lips, face, and hands best distinguish other vascular dysplasias from HHT.</p>
      </sec>
      <sec id="hht.Management">
        <title>Management</title>
        <sec id="hht.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with hereditary hemorrhagic telangiectasia (HHT), the following evaluations are recommended [<xref ref-type="bibr" rid="hht.REF.faughnan.2011.73">Faughnan et al 2011</xref>, <xref ref-type="bibr" rid="hht.REF.mcdonald.2011a.607">McDonald et al 2011a</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Medical history, with particular attention to epistaxis and other bleeding, anemia or polycythemia, diseases of the heart, lung and liver, and neurologic symptoms</p>
            </list-item>
            <list-item>
              <p>Physical examination including inspection for telangiectases (particularly on fingers, lips, tongue, oropharynx, cheeks, or conjunctiva) and listening for abdominal bruits</p>
            </list-item>
            <list-item>
              <p>Complete blood count, with particular attention to anemia or polycythemia. If anemia is present, it is important to consider other causes of anemia, particularly when the anemia appears to be disproportionate to the amount of epistaxis. People with HHT may develop medical problems unrelated to HHT (e.g., ulcers or colon cancer) that can cause GI blood loss. Polycythemia raises suspicion for pulmonary arteriovenous malformations.</p>
            </list-item>
            <list-item>
              <p>Contrast echocardiography for detection of pulmonary shunting/AVM and measurement of the pulmonary artery systolic pressure as a screen for pulmonary artery hypertension. When pulmonary shunting is suggested (or if dependable contrast echocardiography is not available), CT angiography with cuts of 3 mm or less to define size and location of lesions(s) is the next step.</p>
            </list-item>
            <list-item>
              <p>Head MRI (with and without gadolinium) to detect cerebral AVMs, performed as early as possible, preferably in the first year of life. Adults, including those screened with MRI in infancy, should all have a screening head MRI to detect unsuspected vascular lesions and occult cerebral abscesses.</p>
            </list-item>
            <list-item>
              <p>Consideration of ultrasound or CT examination for evidence of hepatic AVM if the individual has symptoms such as high-output failure associated with hepatic vascular abnormalities or otherwise unexplained elevations in liver function tests, or if presence of a visceral AVM would confirm a diagnosis of HHT</p>
              <p>Note: Screening for hepatic AVMs in asymptomatic individuals is not common practice because:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Hepatic AVMs are not usually symptomatic and, when they do become symptomatic, it is not sudden and catastrophic, as is seen with pulmonary AVMs and cerebral AVMs; and</p>
                </list-item>
                <list-item>
                  <p>Treatment options for hepatic AVMs are less satisfactory than those for pulmonary or cerebral AVMs.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="hht.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <sec id="hht.Nosebleeds">
            <title>Nosebleeds</title>
            <p>It is appropriate to consider intervention for nosebleeds in the case of anemia attributable to the nosebleeds or if an individual feels that the frequency or duration interferes significantly with normal activities.</p>
            <p>Humidification and the daily application of nasal lubricants may be helpful.</p>
            <p>Hemostatic products (gauze, sponge or powder products) available over the counter help individuals self-manage significant nosebleeds.</p>
            <p>Laser ablation typically done under general anesthesia may be the most effective intervention for control of mild to moderate nosebleeds. Office-based sclerotherapy was shown to be a potentially safe and useful alternative in an uncontrolled Spanish study [<xref ref-type="bibr" rid="hht.REF.morais.2012.80">Morais et al 2012</xref>] and a small retrospective US pilot study [<xref ref-type="bibr" rid="hht.REF.boyer.2011.319">Boyer et al 2011</xref>].</p>
            <p>Young's nasal closure is a consideration for severe epistaxis which has proven unresponsive to the above methods [<xref ref-type="bibr" rid="hht.REF.richer.2012.401">Richer et al 2012</xref>]. Surgical treatment for severe epistaxis in persons with HHT should be performed by surgeons who treat people with HHT regularly.</p>
            <p>Oral drug therapy. A meta-analysis of studies of hormonal and anti-hormonal treatment concluded that estrogen-progesterone at doses used for oral contraception may eliminate bleeding in symptomatic HHT and is a reasonable initial option to consider for fertile women [<xref ref-type="bibr" rid="hht.REF.jameson.2004.705">Jameson &#x00026; Cave 2004</xref>]. An anti-estrogen, tamoxifen, was reported to decrease nosebleeds in one series [<xref ref-type="bibr" rid="hht.REF.yaniv.2009.284">Yaniv et al 2009</xref>]. Antifibrinolytic drugs such as tranexamic acid (Cyklokapron<sup>&#x000ae;</sup>) have been used with some success in selected individuals; the associated risks are not well established [<xref ref-type="bibr" rid="hht.REF.fernandezl.2007.254">Fernandez-L et al 2007</xref>]. Thalidomide, an angiogenesis inhibitor, reduced the severity and frequency of nosebleeds in six of seven affected individuals in a small series [<xref ref-type="bibr" rid="hht.REF.lebrin.2010.420">Lebrin et al 2010</xref>]. Oral propranolol has also been suggested as a potential treatment [<xref ref-type="bibr" rid="hht.REF.albi_ana.2012.41">Albi&#x000f1;ana et al 2012</xref>].</p>
            <p>Topical drug therapy. Current evidence and experience suggest that the simple humidification and moisturizing effects of medicated sprays and ointments are more helpful than the particular medication. A multi-HHT center randomized, cross-over, placebo controlled trial (NOSE Trial) to study the efficacy of several medicated nose sprays (bevacizumab, estriol, and tranexamic acid) in the treatment of epistaxis concluded that all groups, including the placebo group using saline spray, had a significant improvement in epistaxis. None of the three topical therapies was any better at decreasing epistaxis frequency than twice-daily saline spray [<xref ref-type="bibr" rid="hht.REF.whitehead.2016.943">Whitehead et al 2016</xref>]. Another randomized, multicenter, placebo-controlled clinical trial of three doses of bevacizumab nasal spray was published simultaneously with the NOSE Trial. Here again, topical bevacizumab had no effect on epistaxis [<xref ref-type="bibr" rid="hht.REF.dupuisgirod.2016.934">Dupuis-Girod et al 2016</xref>]. Case reports or small series suggest that these and other topically administered agents (e.g., timolol 0.5% ophthalmic solution) may help reduce the duration or frequency of nosebleeds in those with HHT [<xref ref-type="bibr" rid="hht.REF.flanagan.2012.69">Flanagan et al 2012</xref>, <xref ref-type="bibr" rid="hht.REF.guldmann.2012.953">Guldmann et al 2012</xref>, <xref ref-type="bibr" rid="hht.REF.olitsky.2012.375">Olitsky 2012</xref>, <xref ref-type="bibr" rid="hht.REF.reh.2013.820">Reh et al 2013</xref>].</p>
            <p>Case reports and a small series [<xref ref-type="bibr" rid="hht.REF.bose.2009.2143">Bose et al 2009</xref>, <xref ref-type="bibr" rid="hht.REF.brinkerhoff.2011.688">Brinkerhoff et al 2011</xref>, <xref ref-type="bibr" rid="hht.REF.suppressa.2011.365">Suppressa et al 2011</xref>, <xref ref-type="bibr" rid="hht.REF.dupuisgirod.2012.948">Dupuis-Girod et al 2012</xref>, <xref ref-type="bibr" rid="hht.REF.thompson.2014.91">Thompson et al 2014</xref>] suggest that IV administration of the anti-angiogenic drug bevacizumab may be efficacious in those with severe, intractable nosebleeds.</p>
          </sec>
          <sec id="hht.Gastrointestinal_Bleeding">
            <title>Gastrointestinal Bleeding</title>
            <p>Treatment is unnecessary unless aggressive iron therapy has been ineffective in maintaining hemoglobin concentration in the normal range.</p>
            <p>Endoscopy, capsule endoscopy, mesenteric and celiac angiography, and radionuclide studies may be used to localize the source of bleeding and its type [<xref ref-type="bibr" rid="hht.REF.gr_ve.2010.760">Gr&#x000e8;ve et al 2010</xref>].</p>
            <p>Endoscopic application of a heater probe, bicap, or laser is the mainstay of local treatment.</p>
            <p>Small bowel bleeding sites and larger vascular malformations can be removed surgically after they are identified by nuclear medicine studies.</p>
            <p>For severe GI bleeding associated with intractable iron deficiency anemia, various pharmacologic agents have shown promise based on case reports or small uncontrolled series. Treatment with oral estrogen-progesterone or tranexamic acid has decreased transfusion needs [<xref ref-type="bibr" rid="hht.REF.proctor.2008.756">Proctor et al 2008</xref>]. A number of single cases of dramatic reduction in GI bleeding after IV administration of the anti-angiogenic drug bevacizumab have been reported [<xref ref-type="bibr" rid="hht.REF.flieger.2006.631">Flieger et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.fodstad.2011.611">Fodstad et al 2011</xref>].</p>
          </sec>
          <sec id="hht.Anemia">
            <title>Anemia</title>
            <p>Treatment of anemia with iron replacement and red blood cell transfusion, if necessary, is appropriate.</p>
            <p>Persons with iron deficiency who are intolerant of or do not respond to oral iron benefit from parenteral administration of iron.</p>
          </sec>
          <sec id="hht.Pulmonary_AVMs">
            <title>Pulmonary AVMs</title>
            <p>Treatment of pulmonary AVMs is indicated for dyspnea, exercise intolerance, and hypoxemia, but is most important for prevention of lung hemorrhage and the neurologic complications of brain abscess and stroke, even in those who are asymptomatic with respect to pulmonary function and oxygen saturation. Any pulmonary AVM with a feeding vessel that exceeds 1.0 mm in diameter requires consideration of occlusion [<xref ref-type="bibr" rid="hht.REF.trerotola.2010.837">Trerotola &#x00026; Pyeritz 2010</xref>]. Transcatheter embolotherapy (TCE) with coils, occluder devices (Amplatzer<sup>&#x000ae;</sup>), or both is the treatment of choice. Occasionally, a small lesion cannot be reached because of its location or the size of the feeding vessel. Multiple coils may be needed to occlude AVMs with large or multiple feeding arteries.</p>
            <p>Long-term follow up by chest CT and/or contrast echocardiography is indicated after transcatheter occlusion of pulmonary AVMs because of reported recanalization and development or growth of untreated pulmonary AVMs [<xref ref-type="bibr" rid="hht.REF.cottin.2007.361">Cottin et al 2007</xref>]. Usually a follow-up CT is done six to 12 months post-occlusion, and if no recanalized or new PAVMs are noted, follow-up CT is done at five-year intervals thereafter [<xref ref-type="bibr" rid="hht.REF.trerotola.2010.837">Trerotola &#x00026; Pyeritz 2010</xref>, <xref ref-type="bibr" rid="hht.REF.faughnan.2011.73">Faughnan et al 2011</xref>].</p>
          </sec>
          <sec id="hht.Hepatic_AVMs">
            <title>Hepatic AVMs</title>
            <p>Treatment of cardiac failure or liver failure secondary to hepatic AVMs is currently problematic. Embolization of hepatic AVMs, which is successful for treatment of pulmonary AVMs, has led to lethal hepatic infarctions. Most individuals with symptomatic hepatic AVMs can be satisfactorily managed with intensive medical therapy [<xref ref-type="bibr" rid="hht.REF.buscarini.2011.2166">Buscarini et al 2011</xref>].</p>
            <p>Liver transplantation has been the standard treatment for those (usually older) individuals whose symptoms of hepatic failure do not respond to medical management [<xref ref-type="bibr" rid="hht.REF.buscarini.2006.1040">Buscarini et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.lerut.2006.854">Lerut et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.dupuisgirod.2010.340">Dupuis-Girod et al 2010</xref>, <xref ref-type="bibr" rid="hht.REF.lee.2010.3059">Lee et al 2010</xref>, <xref ref-type="bibr" rid="hht.REF.chavan.2013.106">Chavan et al 2013</xref>].</p>
            <p>Bevacizumab administered intravenously has been reported to decrease cardiac output and symptoms of heart failure in affected individuals with severe symptoms secondary to hepatic AVMs in case reports and one series [<xref ref-type="bibr" rid="hht.REF.mitchell.2008.210">Mitchell et al 2008</xref>, <xref ref-type="bibr" rid="hht.REF.dupuisgirod.2012.948">Dupuis-Girod et al 2012</xref>].</p>
            <p>Liver biopsy should be avoided in individuals with HHT [<xref ref-type="bibr" rid="hht.REF.buscarini.2006.1040">Buscarini et al 2006</xref>].</p>
          </sec>
          <sec id="hht.Cerebral_AVMs">
            <title>Cerebral AVMs</title>
            <p>Cerebral AVMs greater than 1.0 cm in diameter are usually treated using neurovascular surgery, embolotherapy, and/or stereotactic radiosurgery.</p>
            <p>Note: Before proceeding with treatment for any visceral AVM, individuals and their doctors are encouraged to contact the nearest multidisciplinary HHT clinic, which can be located through the support group, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://curehht.org/">Cure HHT</ext-link>, to assure that appropriate diagnostic and treatment plans are in place.</p>
          </sec>
          <sec id="hht.Intestinal_Polyps">
            <title>Intestinal Polyps</title>
            <p>Any individual diagnosed with juvenile polyposis (JP) should be screened for manifestations of HHT, and the family should be screened for polyps. Any person with HHT who has gastrointestinal polyps, especially at an early age, should be evaluated for JP and managed accordingly (see <related-object link-type="booklink" source-id="gene" document-id="jps" document-type="chapter">Juvenile Polyposis Syndrome</related-object>).</p>
          </sec>
        </sec>
        <sec id="hht.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>See <xref ref-type="sec" rid="hht.Treatment_of_Manifestations">Treatment of Manifestations</xref>. Prevention is currently focused at ablating, occluding, resecting or shrinking telangiectases and AVMs to prevent associated morbidity and mortality.</p>
        </sec>
        <sec id="hht.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>If contrast echocardiography is positive for pulmonary shunting, even if no pulmonary AVM is demonstrated by chest CT, a lifetime recommendation for prophylactic antibiotics in accordance with the American Heart Association protocol for dental cleaning and other "dirty" procedures is advised because of the risk of abscess, particularly brain abscess, associated with right to left shunting [<xref ref-type="bibr" rid="hht.REF.dupuisgirod.2007.841">Dupuis-Girod et al 2007</xref>]. For the same reason, an air filter or extreme caution not to introduce air bubbles is recommended with IV lines.</p>
          <p>Note: The risk associated with these lesions is not for subacute bacterial endocarditis (SBE).</p>
        </sec>
        <sec id="hht.Surveillance">
          <title>Surveillance</title>
          <p>The following protocol is recommended for follow up of all individuals for whom the diagnosis of HHT is definite and for all individuals at risk for HHT based on family history in whom HHT has not been ruled out by molecular diagnosis [<xref ref-type="bibr" rid="hht.REF.faughnan.2011.73">Faughnan et al 2011</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Annual evaluation by a health care provider familiar with HHT, including interval history for epistaxis or other bleeding, shortness of breath or decreased exercise tolerance, and headache or other neurologic symptoms</p>
            </list-item>
            <list-item>
              <p>Periodic hematocrit/hemoglobin and ferritin determination with appropriate treatment for iron deficiency anemia</p>
            </list-item>
            <list-item>
              <p>Reevaluation for pulmonary AVM at approximately five-year intervals [<xref ref-type="bibr" rid="hht.REF.nawaz.2008.1582">Nawaz et al 2008</xref>]:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Contrast echocardiogram is used (if available) if the previous contrast echocardiogram did not reveal evidence of a pulmonary or intracardiac right to left shunt.</p>
                </list-item>
                <list-item>
                  <p>Chest CT with contrast rather than pulmonary angiography is used if the previous contrast echocardiogram revealed evidence of a right to left shunt.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Reevaluation for cerebral AVM. While cerebral AVMs are nearly always congenital, development or evolution of cerebral AVMs in the first two decades of life has been reported [<xref ref-type="bibr" rid="hht.REF.hetts.2014.1376">Hetts et al 2014</xref>]. Accordingly, many HHT experts recommend rescreening the brain once more after puberty if the initial brain MRI was done in childhood.</p>
            </list-item>
            <list-item>
              <p>Periodic screening for gastrointestinal polyps and malignant change in persons with juvenile polyps</p>
            </list-item>
          </list>
          <p>
            <bold>Childhood</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Because serious complications of pulmonary and cerebral AVM can occur at any age [<xref ref-type="bibr" rid="hht.REF.meizahav.2006.596">Mei-Zahav et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.curie.2007.299">Curie et al 2007</xref>], screening for pulmonary and cerebral AVMs is recommended in children from families with HHT, especially those with <italic toggle="yes">ENG</italic> pathogenic variants [<xref ref-type="bibr" rid="hht.REF.alsaleh.2009.875">Al-Saleh et al 2009</xref>].</p>
            </list-item>
            <list-item>
              <p>Head MRI with and without gadolinium is recommended as early as the first few months of life [<xref ref-type="bibr" rid="hht.REF.faughnan.2011.73">Faughnan et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p>Pulse oximetry in the supine and sitting positions every one to two years during childhood is recommended as a minimum to screen for pulmonary AVMs. It may be of concern if the sitting value is even a few percentage points below that of the supine value. (Since most pulmonary AVMs are in the lower lobes, many individuals with pulmonary AVMs have higher oxygen saturation when lying than when sitting because of the effect of gravity.) Oxygen saturations below 97% should be followed up with contrast echocardiography. Many, but not all, serious complications of pulmonary AVM during childhood have occurred in hypoxemic children.</p>
            </list-item>
            <list-item>
              <p>By at least age ten years, additional evaluation should be performed by contrast echocardiography, with a follow-up CT if positive.</p>
            </list-item>
          </list>
        </sec>
        <sec id="hht.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Individuals with significant epistaxis are advised to avoid vigorous nose blowing, lifting of heavy objects, straining during bowel movements, and finger manipulation in the nose. Some individuals with HHT experience increased epistaxis after drinking alcohol.</p>
          <p>Most otolaryngologists with experience treating individuals with HHT advise against electric and chemical cautery and transcatheter embolotherapy for treatment of recurrent nosebleeds in most situations.</p>
          <p>Anticoagulants including aspirin and nonsteroidal anti-inflammatory agents such as ibuprofen that interfere with normal clotting should be avoided unless required for treatment of other medical conditions. In one study, lower dose agents, particularly anti-platelet agents, were not associated with hemorrhage in a high proportion of affected individuals. The findings support the use of antiplatelet or anticoagulant agents, with caution, if there is a very strong indication for their use [<xref ref-type="bibr" rid="hht.REF.devlin.2013.876">Devlin et al 2013</xref>].</p>
          <p>Scuba diving should be avoided unless contrast echocardiography performed within the last five years was negative for evidence of a right to left shunt.</p>
          <p>Liver biopsy should be avoided in individuals with HHT [<xref ref-type="bibr" rid="hht.REF.buscarini.2006.1040">Buscarini et al 2006</xref>].</p>
        </sec>
        <sec id="hht.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate at-risk relatives of an affected individual in order to identify as early as possible those who would benefit from preventive measures (see <xref ref-type="sec" rid="hht.Prevention_of_Primary_Manifestations">Prevention of Primary Manifestations</xref>) and prompt initiation of treatment to reduce morbidity and mortality.</p>
          <p>If the pathogenic variant in the family is known, evaluate with molecular genetic testing.</p>
          <p>If the familial pathogenic variant is not known and, consequently, HHT cannot been ruled out by molecular diagnosis, at-risk family members should follow the same protocol as is recommended for individuals in whom the diagnosis of HHT is definite (see <xref ref-type="sec" rid="hht.Surveillance">Surveillance</xref>).</p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals older than age 40 years should have a targeted medical history and clinical examination for features of HHT. The absence of mild but recurrent epistaxis and subtle telangiectases in characteristic locations on careful examination is reassuring.</p>
            </list-item>
            <list-item>
              <p>In individuals age 40 years and younger, targeted medical history and clinical examination for features of HHT in addition to an evaluation for brain and pulmonary AVMs should be done initially, as features of HHT may not be identified by medical history and clinical examination in younger individuals.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="hht.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="hht.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Pregnant women with HHT and untreated pulmonary AVMs are also at high risk for lung hemorrhage and cerebral complications of air embolism. Women with treated pulmonary AVMs appear to be at no higher risk during pregnancy than those without pulmonary AVMs.</p>
        </sec>
        <sec id="hht.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Newer therapies designed to interfere with the development of abnormal vascular connections include thalidomide and bevacizumab; while numerous case reports and small uncontrolled series tout promise, controlled trials are needed [<xref ref-type="bibr" rid="hht.REF.flieger.2006.631">Flieger et al 2006</xref>, <xref ref-type="bibr" rid="hht.REF.mitchell.2008.210">Mitchell et al 2008</xref>, <xref ref-type="bibr" rid="hht.REF.bose.2009.2143">Bose et al 2009</xref>, <xref ref-type="bibr" rid="hht.REF.davidson.2010.432">Davidson et al 2010</xref>, <xref ref-type="bibr" rid="hht.REF.lebrin.2010.420">Lebrin et al 2010</xref>, <xref ref-type="bibr" rid="hht.REF.brinkerhoff.2011.688">Brinkerhoff et al 2011</xref>, <xref ref-type="bibr" rid="hht.REF.fodstad.2011.611">Fodstad et al 2011</xref>, <xref ref-type="bibr" rid="hht.REF.suppressa.2011.365">Suppressa et al 2011</xref>, <xref ref-type="bibr" rid="hht.REF.dupuisgirod.2012.948">Dupuis-Girod et al 2012</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="hht.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="hht.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Hereditary hemorrhagic telangiectasia (HHT) is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="hht.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with HHT have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with HHT may rarely have the disorder as the result of <italic toggle="yes">de novo</italic> germline or somatic pathogenic variant [<xref ref-type="bibr" rid="hht.REF.best.2011.358">Best et al 2011</xref>].</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a child who represents an apparent simplex case (i.e., a single occurrence in a family) include physical examination, documentation of medical history targeted at symptoms and manifestations of HHT, and molecular genetic testing if a pathogenic variant in <italic toggle="yes">ACVRL1</italic>, <italic toggle="yes">ENG</italic>, <italic toggle="yes">GDF2</italic>, or <italic toggle="yes">SMAD4</italic> has been identified in the proband.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in leukocyte DNA of either parent, possible explanations include a <italic toggle="yes">de novo</italic> pathogenic variant in the proband or germline mosaicism in a parent. Though theoretically possible, no instances of germline mosaicism have been reported.</p>
            </list-item>
          </list>
          <p><bold>Sibs of a proband.</bold> The risk to the sibs depends on the genetic status of the proband's parents:</p>
          <list list-type="bullet">
            <list-item>
              <p>If a parent of the proband is affected/has a pathogenic variant, the risk to the sibs of inheriting the variant is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be lower. It should be noted, however, that although highly penetrant, the disease may not present until after age 40 years. Observable symptoms and manifestations can be subtle, even well into adulthood.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is presumed to be slightly greater than that of the general population (though still &#x0003c;1%) because of the theoretic possibility of parental germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with HHT has a 50% chance of inheriting the pathogenic variant.</p>
          <p><bold>Other family members.</bold> The risk to other family members depends on the status of the proband's parents: if a parent is affected or has a pathogenic variant in an HHT-related gene, his or her family members are at risk.</p>
        </sec>
        <sec id="hht.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="hht.Surveillance">Surveillance</xref> and <xref ref-type="sec" rid="hht.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant</bold>. When neither parent of a proband with an autosomal dominant condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <italic toggle="yes">de novo</italic>. However, non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>Testing of at-risk asymptomatic individuals.</bold> Consideration of molecular genetic testing of young, at-risk family members is appropriate for guiding medical management (see <xref ref-type="sec" rid="hht.Surveillance">Surveillance</xref>). Molecular genetic testing can be used with certainty to clarify the genetic status of at-risk family members when a clinically diagnosed relative has undergone molecular genetic testing and is found to have a pathogenic variant in an HHT-related gene.</p>
          <p>Testing of asymptomatic at-risk family members usually involves pre-test consultation to discuss the possible impact of positive and negative test results. Those seeking testing should be counseled regarding possible problems that they may encounter with respect to health, life, and disability insurance coverage, employment and educational discrimination, and changes in social and family interaction. Informed consent should be procured and records kept confidential. Individuals identified to have a pathogenic variant in one of the four HHT-related genes need long-term follow up and evaluations. Although identifying affected relatives when the familial pathogenic variant is known results in considerable savings of healthcare costs over the life of the at-risk relative, for a variety of reasons, individuals at 50% risk for inheriting HHT often decline molecular genetic testing when the familial pathogenic variant is known [<xref ref-type="bibr" rid="hht.REF.bernhardt.2012.604">Bernhardt et al 2012</xref>].</p>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, genotype-phenotype correlations, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="hht.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the pathogenic variant in <italic toggle="yes">ACVRL1</italic>, <italic toggle="yes">ENG</italic>, <italic toggle="yes">GDF2</italic>, or <italic toggle="yes">SMAD4</italic> has been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis are possible.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="hht.Resources">
        <title>Resources</title>
      </sec>
      <sec id="hht.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="hht.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Currently, all known genetic defects that cause HHT are in genes that encode proteins within the transforming growth factor beta (TGF-&#x003b2;) signaling pathway.</p>
          <sec id="hht.ACVRL1">
            <title>
              <italic toggle="yes">ACVRL1</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">ACVRL1</italic> contains ten exons and spans approximately 14 kb of genomic DNA. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hht" object-id="hht.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic variants.</bold> Current data suggest that most of pathogenic variants in <italic toggle="yes">ACVRL1</italic> are functionally null alleles [<xref ref-type="bibr" rid="hht.REF.berg.1997.60">Berg et al 1997</xref>, <xref ref-type="bibr" rid="hht.REF.pece.1997.2568">Pece et al 1997</xref>, <xref ref-type="bibr" rid="hht.REF.gallione.1998.286">Gallione et al 1998</xref>, <xref ref-type="bibr" rid="hht.REF.richardsyutz.2010.61">Richards-Yutz et al 2010</xref>]. No common pathogenic variants have been identified. The frequency of pathogenic variants is highest in exons 8, 7, and 3, but these account for only 65% of pathogenic variants identified and variants have been identified in all exons. Missense variants account for more than half (53%) of pathogenic variants detected; deletions, insertions, and splice site variants have also been reported [<xref ref-type="bibr" rid="hht.REF.abdalla.2006.97">Abdalla &#x00026; Letarte 2006</xref>, <xref ref-type="bibr" rid="hht.REF.richardsyutz.2010.61">Richards-Yutz et al 2010</xref>]. (For more information, see <related-object source-id="gene" document-id="hht" object-id="hht.molgen.TA">Table A</related-object>.)</p>
            <p><bold>Normal gene product.</bold> Serine/threonine-protein kinase receptor R3 is a type I cell-surface receptor for the TGF-superfamily of ligands. It is expressed predominantly on endothelial cells [<xref ref-type="bibr" rid="hht.REF.abdalla.2006.97">Abdalla &#x00026; Letarte 2006</xref>].</p>
            <p><bold>Abnormal gene product.</bold> Current data suggest that most pathogenic variants in <italic toggle="yes">ACVRL1</italic> result in loss of protein expression. HHT is assumed to be the result of haploinsufficiency [<xref ref-type="bibr" rid="hht.REF.abdalla.2006.97">Abdalla &#x00026; Letarte 2006</xref>].</p>
          </sec>
          <sec id="hht.ENG">
            <title>
              <italic toggle="yes">ENG</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">ENG</italic> contains 14 exons and spans approximately 40 kb of genomic DNA. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hht" object-id="hht.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic variants.</bold> Current data suggest that approximately two thirds of variants in <italic toggle="yes">ENG</italic> are functionally null alleles [<xref ref-type="bibr" rid="hht.REF.berg.1997.60">Berg et al 1997</xref>, <xref ref-type="bibr" rid="hht.REF.pece.1997.2568">Pece et al 1997</xref>, <xref ref-type="bibr" rid="hht.REF.gallione.1998.286">Gallione et al 1998</xref>, <xref ref-type="bibr" rid="hht.REF.richardsyutz.2010.61">Richards-Yutz et al 2010</xref>]. There are no common pathogenic variants. The total number of variants per exon is similar with the exception of exons 1, 9b, 12, and 13, which have fewer variants. Pathogenic variants of all types have been reported [<xref ref-type="bibr" rid="hht.REF.abdalla.2006.97">Abdalla &#x00026; Letarte 2006</xref>]. (For more information, see <related-object source-id="gene" document-id="hht" object-id="hht.molgen.TA">Table A</related-object>.)</p>
            <p><bold>Normal gene product.</bold> Endoglin is a component of the transforming growth factor beta (TGF-beta) receptor complex. It is expressed predominantly on endothelial cells.</p>
            <p><bold>Abnormal gene product.</bold> Current data suggest that most pathogenic variants in <italic toggle="yes">ENG</italic> result in loss of protein expression. HHT is assumed to be the result of haploinsufficiency [<xref ref-type="bibr" rid="hht.REF.abdalla.2006.97">Abdalla &#x00026; Letarte 2006</xref>].</p>
          </sec>
          <sec id="hht.GDF2">
            <title>
              <italic toggle="yes">GDF2</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">GDF2</italic> (also known as <italic toggle="yes">BMP9</italic>) is a small gene comprising two exons and a transcript of 1955 bp (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_016204.2">NM_016204.2</ext-link>). For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hht" object-id="hht.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic variants.</bold> Missense variants in <italic toggle="yes">GDF2</italic> were identified in three individuals with features of HHT including epistaxis [<xref ref-type="bibr" rid="hht.REF.wooderchakdonahue.2013.530">Wooderchak-Donahue et al 2013</xref>].</p>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">GDF2</italic> encodes growth/differentiation factor 2 (also known as <italic toggle="yes">BMP9</italic> or bone morphogenetic protein 9), a protein of 429 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_057288.1">NP_057288.1</ext-link>). After post-translational cleavage of the signal peptide and the propeptide, the mature peptide is 110 amino acid residues. It is a member of the bone morphogenetic protein family and the TGF-beta superfamily. The members of this family are regulators of cell growth and differentiation in both embryonic and adult tissues.</p>
            <p><bold>Abnormal gene product.</bold> Cell culture studies suggested that these variants resulted in loss of mature protein and/or function. A <italic toggle="yes">bmp9</italic>-deficient zebrafish model demonstrated that <italic toggle="yes">BMP9</italic> is involved in angiogenesis [<xref ref-type="bibr" rid="hht.REF.wooderchakdonahue.2013.530">Wooderchak-Donahue et al 2013</xref>].</p>
          </sec>
          <sec id="hht.SMAD4">
            <title>
              <italic toggle="yes">SMAD4</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">SMAD4</italic> contains 11 exons and has a cDNA of 2680 bp. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="hht" object-id="hht.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic variants.</bold> There are no common pathogenic variants and all types of variants have been described. More than two thirds of pathogenic variants reported are functionally null alleles (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://arup.utah.edu/database/SMAD4/SMAD4_display.php"><italic toggle="yes">SMAD4</italic> Database</ext-link>). Although <italic toggle="yes">SMAD4</italic> pathogenic variants in individuals with <related-object link-type="booklink" source-id="gene" document-id="jps" document-type="chapter">JP</related-object>-HHT have shown a tendency to cluster in the MH2 domain, pathogenic variants in other parts of the gene also cause the combined syndrome. Any individual with an <italic toggle="yes">SMAD4</italic> pathogenic variant should be considered at risk for manifestations of both JP and HHT [<xref ref-type="bibr" rid="hht.REF.gallione.2010.333">Gallione et al 2010</xref>, <xref ref-type="bibr" rid="hht.REF.omalley.2012.886">O'Malley et al 2012</xref>].</p>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">SMAD4</italic> encodes a 552-amino acid protein that functions as an intracellular signaling molecule in the TGF-beta/BMP pathway.</p>
            <p><bold>Abnormal gene product.</bold> Most pathogenic variants in <italic toggle="yes">SMAD4</italic> result in non-expressed proteins. HHT is assumed to be the result of haploinsufficiency.</p>
          </sec>
        </sec>
      </sec>
      <sec id="hht.References">
        <title>References</title>
        <sec id="hht.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="hht.Literature_Cited.reflist0">
            <ref id="hht.REF.aassar.1991.977">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aassar</surname>
                    <given-names>OS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>RI</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <article-title>The natural history of epistaxis in hereditary hemorrhagic telangiectasia.</article-title>
                <source>Laryngoscope.</source>
                <year>1991</year>
                <volume>101</volume>
                <fpage>977</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">1886446</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.abdalla.2006.97">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Abdalla</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Letarte</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>97</fpage>
                <lpage>110</lpage>
                <pub-id pub-id-type="pmid">15879500</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.albi_ana.2012.41">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Albi&#x000f1;ana</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Recio-Poveda</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zarrabeitia</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernab&#x000e9;u</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Botella</surname>
                    <given-names>LM</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Propranolol as antiangiogenic candidate for the therapy of hereditary hemorrhagic telangiectasia.</article-title>
                <source>Thromb Haemost</source>
                <volume>108</volume>
                <fpage>41</fpage>
                <lpage>53</lpage>
                <pub-id pub-id-type="pmid">22552254</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.alsaleh.2009.875">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Al-Saleh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mei-Zahav</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faughnan</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacLusky</surname>
                    <given-names>IB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Letarte</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ratjen</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Screening for pulmonary and cerebral arteriovenous malformations in children with hereditary haemorrhagic telangiectasia.</article-title>
                <source>Eur Respir J.</source>
                <volume>34</volume>
                <fpage>875</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">19386691</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.austin.2013">
              <mixed-citation publication-type="book">Austin ED, Newman JH, Loyd JE, Phillips JA III. Heritable and idiopathic forms of pulmonary arterial hypertension. In: Rimoin DL, Pyeritz RE, Korf BR, eds. <italic toggle="yes">Emery and Rimoin's Principles and Practice of Medical Genetics</italic>. 6 ed. Chap 48. Academic Press; 2013.</mixed-citation>
            </ref>
            <ref id="hht.REF.bayraktoydemir.2006a.2155">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bayrak-Toydemir</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akarsu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toydemir</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calderon</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tuncali</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mao</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2006a</year>
                <article-title>A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7.</article-title>
                <source>Am J Med Genet A</source>
                <volume>140</volume>
                <fpage>2155</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">16969873</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.bayraktoydemir.2006b.463">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bayrak-Toydemir</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Markewitz</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chou</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gedge</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coon</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mao</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2006b</year>
                <article-title>Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: mutations and manifestations.</article-title>
                <source>Am J Med Genet A</source>
                <volume>140</volume>
                <fpage>463</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">16470787</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.berg.2003.585">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Berg</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porteous</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reinhardt</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallione</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holloway</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Umasunthar</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lux</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKinnon</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchuk</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guttmacher</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations.</article-title>
                <source>J Med Genet</source>
                <volume>40</volume>
                <fpage>585</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">12920067</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.berg.1997.60">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Berg</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallione</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stenzel</surname>
                    <given-names>TT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allen</surname>
                    <given-names>WP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porteous</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchuk</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2.</article-title>
                <source>Am J Hum Genet</source>
                <volume>61</volume>
                <fpage>60</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9245985</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.bernhardt.2012.604">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bernhardt</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zayac</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trerotola</surname>
                    <given-names>SO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asch</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pyeritz</surname>
                    <given-names>RE</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Cost savings through molecular diagnosis for hereditary hemorrhagic telangiectasia.</article-title>
                <source>Genet Med</source>
                <volume>14</volume>
                <fpage>604</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">22281938</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.best.2011.358">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Best</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaughn</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Damjanovich</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Runo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chibuk</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayrak-Toydemir</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Mosaic ACVRL1 and ENG mutations in hereditary haemorrhagic telangiectasia patients.</article-title>
                <source>J Med Genet</source>
                <volume>48</volume>
                <fpage>358</fpage>
                <lpage>360</lpage>
                <pub-id pub-id-type="pmid">21378382</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.bharatha.2012.72">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bharatha</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faughnan</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pourmohamad</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krings</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayrak-Toydemir</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pawlikowska</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCulloch</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawton</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dowd</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terbrugge</surname>
                    <given-names>KG</given-names>
                  </name>
                </person-group>
                <article-title>Brain arteriovenous malformation multiplicity predicts the diagnosis of hereditary hemorrhagic telangiectasia: quantitative assessment.</article-title>
                <source>Stroke</source>
                <year>2012</year>
                <volume>43</volume>
                <fpage>72</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">22034007</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.bose.2009.2143">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bose</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holter</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Selby</surname>
                    <given-names>GB</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Bevacizumab in hereditary hemorrhagic telangiectasia.</article-title>
                <source>N Engl J Med</source>
                <volume>360</volume>
                <fpage>2143</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">19439755</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.bossler.2006.667">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bossler</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>George</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Godmilow</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganguly</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Novel mutations in ENG and ACVRL1 identified in a series of 200 individuals undergoing clinical genetic testing for hereditary hemorrhagic telangiectasia (HHT): correlation of genotype with phenotype.</article-title>
                <source>Hum Mutat</source>
                <volume>27</volume>
                <fpage>667</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">16752392</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.boyer.2011.319">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boyer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandes</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duran</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunter</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goding</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <article-title>Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia: a pilot study.</article-title>
                <source>Int Forum Allergy Rhinol.</source>
                <year>2011</year>
                <volume>1</volume>
                <fpage>319</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">22287439</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.brenard.2010.1253">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brenard</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapaux</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deltenre</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henrion</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Maeght</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horsmans</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borbath</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leenaerts</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Cauter</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Francque</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serst&#x000e9;</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moreno</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orlent</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mengeot</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lerut</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sempoux</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Large spectrum of liver vascular lesions including high prevalence of focal nodular hyperplasia in patients with hereditary haemorrhagic telangiectasia: the Belgian Registry based on 30 patients.</article-title>
                <source>Eur J Gastroenterol Hepatol.</source>
                <year>2010</year>
                <volume>22</volume>
                <fpage>1253</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20631626</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.brinkerhoff.2011.688">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brinkerhoff</surname>
                    <given-names>BT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poetker</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choong</surname>
                    <given-names>NW</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia.</article-title>
                <source>N Engl J Med</source>
                <volume>364</volume>
                <fpage>688</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21323562</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.brusgaard.2004.556">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brusgaard</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kjeldsen</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poulsen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moss</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vase</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rasmussen</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kruse</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>H&#x000f8;rder</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Mutations in endoglin and in activin receptor-like kinase 1 among Danish patients with hereditary haemorrhagic telangiectasia.</article-title>
                <source>Clin Genet</source>
                <volume>66</volume>
                <fpage>556</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">15521985</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.buscarini.2004a.348">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Buscarini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danesino</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olivieri</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lupinacci</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Grazia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reduzzi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blotta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gazzaniga</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagella</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grosso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pongiglione</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buscarini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zambelli</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004a</year>
                <article-title>Doppler ultrasonographic grading of hepatic vascular malformations in hereditary hemorrhagic telangiectasia -- results of extensive screening.</article-title>
                <source>Ultraschall Med</source>
                <volume>25</volume>
                <fpage>348</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">15368138</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.buscarini.2004b.1089">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Buscarini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danesino</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Fazio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olivieri</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brambilla</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menozzi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reduzzi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blotta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gazzaniga</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagella</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grosso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pongiglione</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cappiello</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zambelli</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004b</year>
                <article-title>High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia.</article-title>
                <source>Ultrasound Med Biol</source>
                <volume>30</volume>
                <fpage>1089</fpage>
                <lpage>97</lpage>
                <pub-id pub-id-type="pmid">15550313</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.buscarini.2011.2166">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Buscarini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leandro</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conte</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danesino</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daina</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manfredi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lupinacci</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brambilla</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Menozzi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Grazia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gazzaniga</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inama</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonardi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blotta</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Forner</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olivieri</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perna</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grosso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pongiglione</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boccardi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagella</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rossi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zambelli</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia.</article-title>
                <source>Dig Dis Sci.</source>
                <volume>56</volume>
                <fpage>2166</fpage>
                <lpage>78</lpage>
                <pub-id pub-id-type="pmid">21290179</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.buscarini.2006.1040">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Buscarini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia Tsao</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>RI</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Sabb&#x000e0;</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saurin</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pelage</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lesca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marion</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perna</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faughnan</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations.</article-title>
                <source>Liver Int.</source>
                <volume>26</volume>
                <fpage>1040</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">17032403</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.chavan.2013.106">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chavan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schumann-Binarsch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luthe</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nickau</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Els&#x000e4;sser</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000fc;hnel</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geisthoff</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>K&#x000f6;hne</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Systemic therapy with bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).</article-title>
                <source>Vasa.</source>
                <year>2013</year>
                <volume>42</volume>
                <fpage>106</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">23485837</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.cole.2005.577">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cole</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Begbie</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shovlin</surname>
                    <given-names>CL</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5.</article-title>
                <source>J Med Genet</source>
                <volume>42</volume>
                <fpage>577</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">15994879</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.cottin.2007.361">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cottin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dupuis-Girod</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lesca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordier</surname>
                    <given-names>JF</given-names>
                  </name>
                </person-group>
                <article-title>Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (rendu-osler disease).</article-title>
                <source>Respiration.</source>
                <year>2007</year>
                <volume>74</volume>
                <fpage>361</fpage>
                <lpage>78</lpage>
                <pub-id pub-id-type="pmid">17641482</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.curie.2007.299">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Curie</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lesca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cottin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Edery</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellon</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faughnan</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Long-term follow-up in 12 children with pulmonary arteriovenous malformations: confirmation of hereditary hemorrhagic telangiectasia in all cases.</article-title>
                <source>J Pediatr</source>
                <volume>151</volume>
                <fpage>299</fpage>
                <lpage>306</lpage>
                <pub-id pub-id-type="pmid">17719943</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.davidson.2010.432">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davidson</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olitsky</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wei</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Hereditary hemorrhagic telangiectasia/avastin.</article-title>
                <source>Laryngoscope</source>
                <volume>120</volume>
                <fpage>432</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19998344</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.devlin.2013.876">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Devlin</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hosman</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shovlin</surname>
                    <given-names>CL</given-names>
                  </name>
                </person-group>
                <article-title>Antiplatlet and anticoagulant agents in hereditary hemorrhagic telangiectasia.</article-title>
                <source>N Engl J Med.</source>
                <year>2013</year>
                <volume>368</volume>
                <fpage>876</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">23445111</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.dupuisgirod.2012.948">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dupuis-Girod</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginon</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saurin</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marion</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guillot</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Decullier</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roux</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carette</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilbert-Dussardier</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hatron</surname>
                    <given-names>PY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorcerie</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivi&#x000e8;re</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corre</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraud</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bailly</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paintaud</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ternant</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valette</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faure</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Bevacizumab in patients with HHT and severe hepatic vascular malformations and high cardiac output.</article-title>
                <source>JAMA</source>
                <year>2012</year>
                <volume>307</volume>
                <fpage>948</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">22396517</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.dupuisgirod.2010.340">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dupuis-Girod</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chesnais</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ginon</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dumortier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saurin</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Finet</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Decullier</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marion</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boillot</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Long-term outcome of patients with hereditary hemorrhagic telangiectasia and severe hepatic involvement after orthotopic liver transplantation: a single-center study.</article-title>
                <source>Liver Transpl.</source>
                <volume>16</volume>
                <fpage>340</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20209594</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.dupuisgirod.2007.841">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dupuis-Girod</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraud</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Decullier</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lesca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cottin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faure</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merrot</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saurin</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordier</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Hemorrhagic hereditary telangiectasia (Rendu-Osler disease) and infectious diseases: an underestimated association.</article-title>
                <source>Clin Infect Dis.</source>
                <year>2007</year>
                <volume>44</volume>
                <fpage>841</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">17304458</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.dupuisgirod.2016.934">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dupuis-Girod</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ambrun</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Decullier</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fargeton</surname>
                    <given-names>A-E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roux</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Br&#x000e9;ant</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colombet</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivi&#x000e8;re</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cartier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinet</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilvet</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blondel</surname>
                    <given-names>J-H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilvert-Dussardier</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dufour</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michel</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harle</surname>
                    <given-names>J-R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dessi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faure</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangiectasia: a randomized clinic trial.</article-title>
                <source>JAMA</source>
                <year>2016</year>
                <volume>316</volume>
                <fpage>934</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">27599328</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.eerola.2003.1240">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eerola</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boon</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulliken</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burrows</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dompmartin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watanabe</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanwijck</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vikkula</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations.</article-title>
                <source>Am J Hum Genet</source>
                <volume>73</volume>
                <fpage>1240</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14639529</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.faughnan.2011.73">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Faughnan</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palda</surname>
                    <given-names>VA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Tsao</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geisthoff</surname>
                    <given-names>UW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proctor</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spears</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buscarini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chesnutt</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cottin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganguly</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gossage</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guttmacher</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kennedy</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korzenik</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mager</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozanne</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piccirillo</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Picus</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Porteous</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pyeritz</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabba</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swanson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terry</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wallace</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westermann</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>RI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zarrabeitia</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia.</article-title>
                <source>J Med Genet.</source>
                <year>2011</year>
                <volume>48</volume>
                <fpage>73</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">19553198</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.faughnan.2004.826">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Faughnan</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thabet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mei-Zahav</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colombo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maclusky</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pugash</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chait</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henderson</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>RI</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Pulmonary arteriovenous malformations in children: outcomes of transcatheter embolotherapy.</article-title>
                <source>J Pediatr</source>
                <volume>145</volume>
                <fpage>826</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">15580209</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.fernandezl.2007.254">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fernandez-L</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garrido-Martin</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanz-Rodriguez</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramirez</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morales-Angulo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zarrabeitia</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Perez-Molino</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernab&#x000e9;u</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Botella</surname>
                    <given-names>LM</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells.</article-title>
                <source>Thromb Haemost</source>
                <volume>97</volume>
                <fpage>254</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">17264955</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.flanagan.2012.69">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Flanagan</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parra</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Intranasal tranexamic acid for the treatment of HHT: a case report and review of treatment options.</article-title>
                <source>Cutis.</source>
                <volume>89</volume>
                <fpage>69</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">22474728</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.flieger.2006.631">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Flieger</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hainke</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischbach</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Dramatic improvement in HHT after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab.</article-title>
                <source>Ann Hematol.</source>
                <volume>85</volume>
                <fpage>631</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">16807748</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.fodstad.2011.611">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fodstad</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dheyauldeen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinde</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bachmann-Harildstad</surname>
                    <given-names>G.</given-names>
                  </name>
                </person-group>
                <article-title>Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe HHT.</article-title>
                <source>Ann Hematol.</source>
                <year>2011</year>
                <volume>90</volume>
                <fpage>611</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">20824275</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.gallione.2010.333">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gallione</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aylsworth</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berk</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernhardt</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clericuzio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danesino</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drautz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fahl</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fan</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faughnan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganguly</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garvie</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henderson</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kini</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leedom</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ludman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lux</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maisenbacher</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maxxucco</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olivieri</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ploos van Amstel</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prigoda-Lee</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pyeritz</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reardon</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vandeznade</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wladman</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>RI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchuk</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Overlapping spectra of SMAD4 mutations in juvenile polyposis and JP-HHT syndrome.</article-title>
                <source>Am J Med Genet</source>
                <volume>152A</volume>
                <fpage>333</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20101697</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.gallione.1998.286">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gallione</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klaus</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yeh</surname>
                    <given-names>EY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stenzel</surname>
                    <given-names>TT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xue</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anthony</surname>
                    <given-names>KB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McAllister</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baldwin</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berg</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lux</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vary</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craigen</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westermann</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warner</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>YE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jackson</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guttmacher</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchuk</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Mutation and expression analysis of the endoglin gene in hereditary hemorrhagic telangiectasia reveals null alleles.</article-title>
                <source>Hum Mutat</source>
                <volume>11</volume>
                <fpage>286</fpage>
                <lpage>94</lpage>
                <pub-id pub-id-type="pmid">9554745</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.gallione.2004.852">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gallione</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Repetto</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Legius</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rustgi</surname>
                    <given-names>AK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schelley</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tejpar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drouin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westermann</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchuk</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).</article-title>
                <source>Lancet</source>
                <volume>363</volume>
                <fpage>852</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15031030</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.gallione.2006.793">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gallione</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richards</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Letteboer</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rushlow</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prigoda</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leedom</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganguly</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castells</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ploos van Amstel</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westermann</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pyeritz</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchuk</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>SMAD4 mutations found in unselected HHT patients.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>793</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16613914</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.garciatsao.2000.931">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Garcia-Tsao</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korzenik</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henderson</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jain</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byrd</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pollak</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>RI</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Liver disease in patients with hereditary hemorrhagic telangiectasia.</article-title>
                <source>N Engl J Med</source>
                <volume>343</volume>
                <fpage>931</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11006369</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.gedge.2007.258">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gedge</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phansalkar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chou</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calderon</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mao</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyon</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayrak-Toydemir</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Clinical and analytical sensitivities in hereditary hemorrhagic telangiectasia testing and a report of de novo mutations.</article-title>
                <source>J Mol Diagn</source>
                <volume>9</volume>
                <fpage>258</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">17384219</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.girerd.2010.851">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Girerd</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montani</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coulet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sztrymf</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yaici</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ja&#x000ef;s</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tregouet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drouin-Garraud</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fraisse</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sitbon</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Callaghan</surname>
                    <given-names>DS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonneau</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Soubrier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humbert</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation.</article-title>
                <source>Am J Respir Crit Care Med.</source>
                <volume>181</volume>
                <fpage>851</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">20056902</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.gr_ve.2010.760">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gr&#x000e8;ve</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moussata</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gaudin</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lapalus</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraud</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dupuis-Girod</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calender</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saurin</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>High diagnostic and clinical impact of small-bowel capsule endoscopy in patients with hereditary hemorrhagic telangiectasia with overt digestive bleeding and/or severe anemia.</article-title>
                <source>Gastrointest Endosc.</source>
                <volume>71</volume>
                <fpage>760</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20170910</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.guldmann.2012.953">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guldmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dupret</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nivoix</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schultz</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Debry</surname>
                    <given-names>Cl</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Bevacizumab nasal spray: noninvasive treatment of epistaxis in patients with Rendu-Olser disease.</article-title>
                <source>Laryngoscope.</source>
                <volume>122</volume>
                <fpage>953</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">22447341</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.guttmacher.2013">
              <mixed-citation publication-type="book">Guttmacher AE, Marchuck D, Trerotola SO, Pyeritz RE. Hereditary hemorrhagic telangiectasia. In: Rimoin DL, Pyeritz RE, Korf BR, eds. <italic toggle="yes">Emery and Rimoin's Principles and Practice of Medical Genetics</italic>. 6 ed. Chap 49. Academic Press; 2013.</mixed-citation>
            </ref>
            <ref id="hht.REF.hetts.2014.1376">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hetts</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooke</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gupta</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fullerton</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amans</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Narvid</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moftakhar</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McSwain</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dowd</surname>
                    <given-names>CF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Higashida</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halbach</surname>
                    <given-names>VV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawton</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Influence of patient age on angioarchitecture of brain arteriovenous malformations.</article-title>
                <source>Am J Neuroradiol</source>
                <year>2014</year>
                <volume>35</volume>
                <fpage>1376</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">24627452</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.howe.2004.484">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Howe</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sayed</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmed</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ringold</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larsen-Haidle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitros</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vaccaro</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petersen</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giardiello</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tinley</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aaltonen</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lynch</surname>
                    <given-names>HT</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations.</article-title>
                <source>J Med Genet</source>
                <volume>41</volume>
                <fpage>484</fpage>
                <lpage>91</lpage>
                <pub-id pub-id-type="pmid">15235019</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.ianora.2004.250">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ianora</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Memeo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabba</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cirulli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rotondo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelelli</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Hereditary hemorrhagic telangiectasia: multi-detector row helical CT assessment of hepatic involvement.</article-title>
                <source>Radiology</source>
                <volume>230</volume>
                <fpage>250</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14645886</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.jameson.2004.705">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jameson</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cave</surname>
                    <given-names>DR</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Hormonal and antihormonal therapy for epistaxis in hereditary hemorrhagic telangiectasia.</article-title>
                <source>Laryngoscope</source>
                <volume>114</volume>
                <fpage>705</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15064628</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.kjeldsen.2000.415">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kjeldsen</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kjeldsen</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia.</article-title>
                <source>Am J Gastroenterol</source>
                <volume>95</volume>
                <fpage>415</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10685743</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.kjeldsen.2005.349">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kjeldsen</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000f8;ller</surname>
                    <given-names>TR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brusgaard</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vase</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>PE</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Clinical symptoms according to genotype amongst patients with hereditary haemorrhagic telangiectasia.</article-title>
                <source>J Intern Med</source>
                <volume>258</volume>
                <fpage>349</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">16164574</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.lacout.2010.479">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lacout</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pelage</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lesur</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinet</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beauchet</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roume</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacombe</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Pancreatic involvement in hereditary hemorrhagic telangiectasia: assessment with multidetector helical CT.</article-title>
                <source>Radiology.</source>
                <year>2010</year>
                <volume>254</volume>
                <fpage>479</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">20093519</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.lebrin.2010.420">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lebrin</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srun</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raymond</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Brink</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freitas</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Br&#x000e9;ant</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathivet</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larriv&#x000e9;e</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arthur</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westermann</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Disch</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mager</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snijder</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eichmann</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mummery</surname>
                    <given-names>CL</given-names>
                  </name>
                </person-group>
                <article-title>Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia.</article-title>
                <source>Nat Med.</source>
                <year>2010</year>
                <volume>16</volume>
                <fpage>420</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20364125</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.lee.2010.3059">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sze</surname>
                    <given-names>DY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonham</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daugherty</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Hepatic arteriovenous malformations from hereditary hemorrhagic telangiectasia: treatment with liver transplantation.</article-title>
                <source>Dig Dis Sci</source>
                <volume>55</volume>
                <fpage>3059</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">20844961</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.lenato.2006.213">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lenato</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lastella</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Giacomo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Resta</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suppressa</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasculli</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabb&#x000e0;</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guanti</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>DHPLC-based mutation analysis of ENG and ALK-1 genes in HHT Italian population.</article-title>
                <source>Hum Mutat</source>
                <volume>27</volume>
                <fpage>213</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">16429404</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.lerut.2006.854">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lerut</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orlando</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adam</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabb&#x000e0;</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pfitzmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klempnauer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Belghiti</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pirenne</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thevenot</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hillert</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonze</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karam</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boillot</surname>
                    <given-names>O</given-names>
                  </name>
                  <etal/>
                </person-group>
                <year>2006</year>
                <article-title>Liver transplantation for hereditary hemorrhagic telangiectasia: Report of the European liver transplant registry.</article-title>
                <source>Ann Surg</source>
                <volume>244</volume>
                <fpage>854</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">17122610</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.lesca.2006.598">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lesca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burnichon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raux</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tosi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marion</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Babin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilbert-Dussardier</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivi&#x000e8;re</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goizet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faivre</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fr&#x000e9;bourg</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calender</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraud</surname>
                    <given-names>S</given-names>
                  </name>
                  <etal/>
                </person-group>
                <year>2006</year>
                <article-title>Distribution of ENG and ACVRL1 (ALK1) mutations in French HHT patients.</article-title>
                <source>Hum Mutat</source>
                <volume>27</volume>
                <fpage>598</fpage>
                <pub-id pub-id-type="pmid">16705692</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.lesca.2007.14">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lesca</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olivieri</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burnichon</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagella</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carette</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilbert-Dussardier</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goizet</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roume</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rabilloud</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saurin</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cottin</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Honnorat</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coulet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giraud</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calender</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danesino</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buscarini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                  <etal/>
                </person-group>
                <article-title>Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network.</article-title>
                <source>Genet Med.</source>
                <year>2007</year>
                <volume>9</volume>
                <fpage>14</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">17224686</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.letteboer.2006.371">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Letteboer</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mager</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snijder</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeleman</surname>
                    <given-names>BP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindhout</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ploos van Amstel</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westermann</surname>
                    <given-names>CJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Genotype-phenotype relationship in hereditary haemorrhagic telangiectasia.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>371</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16155196</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.letteboer.2005.8">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Letteboer</surname>
                    <given-names>TG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zewald</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamping</surname>
                    <given-names>EJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Haas</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mager</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Snijder</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindhout</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hennekam</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westermann</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ploos van Amstel</surname>
                    <given-names>JK</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Hereditary hemorrhagic telangiectasia: ENG and ALK-1 mutations in Dutch patients.</article-title>
                <source>Hum Genet</source>
                <volume>116</volume>
                <fpage>8</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">15517393</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.marchuk.1998.269">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marchuk</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guttmacher</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Penner</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganguly</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Report on the workshop on Hereditary Hemorrhagic Telangiectasia, July 10-11, 1997.</article-title>
                <source>Am J Med Genet</source>
                <volume>76</volume>
                <fpage>269</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">9508248</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.mcdonald.2011a.607">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayrak-Toydemir</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pyeritz</surname>
                    <given-names>RE</given-names>
                  </name>
                </person-group>
                <year>2011a</year>
                <article-title>Hereditary hemorrhagic telangiectasia: An overview of diagnosis, management and pathogenesis.</article-title>
                <source>Genet Med</source>
                <volume>13</volume>
                <fpage>607</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">21546842</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.mcdonald.2011b.335">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Damjanovich</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Millson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wooderchak</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chibuk</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevenson</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gedge</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayrak-Toydemir</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2011b</year>
                <article-title>Molecular diagnosis in hereditary hemorrhagic telangiectasia: findings in a series tested simultaneously by sequencing and deletion/duplication analysis.</article-title>
                <source>Clin Genet</source>
                <volume>79</volume>
                <fpage>335</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">21158752</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.mcdonald.2015.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wooderchak-Donahue</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>VanSant Webb</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whitehead</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevenson</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayrak-Toydemir</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>Hereditary hemorrhagic telangiectasia: genetics and molecular diagnostics in a new era.</article-title>
                <source>Front Genet.</source>
                <year>2015</year>
                <volume>6</volume>
                <fpage>1</fpage>
                <pub-id pub-id-type="pmid">25674101</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.meizahav.2006.596">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mei-Zahav</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Letarte</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faughnan</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdalla</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cymerman</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacLusky</surname>
                    <given-names>IB</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Symptomatic Children with Hereditary Hemorrhagic Telangiectasia.</article-title>
                <source>Arch Pediatr Adolesc Med</source>
                <volume>160</volume>
                <fpage>596</fpage>
                <lpage>601</lpage>
                <pub-id pub-id-type="pmid">16754821</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.mitchell.2008.210">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacQuillan</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tibballs</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>vanden Driesen R, Delriviere L. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia.</article-title>
                <source>Liver Transpl.</source>
                <year>2008</year>
                <volume>14</volume>
                <fpage>210</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">18236396</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.mohler.2009.356">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mohler</surname>
                    <given-names>ER</given-names>
                    <suffix>III</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Doriswamy</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sibley</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernhardt</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pyeritz</surname>
                    <given-names>RE</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Transillumination of the fingers for vascular anomalies: a novel method for evaluating hereditary hemorrhagic telangiectasia.</article-title>
                <source>Genet Med</source>
                <volume>11</volume>
                <fpage>356</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19365270</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.morais.2012.80">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morais</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mill&#x000e1;s</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zarrabeitia</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Botella</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Almaraz</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Local sclerotherapy with Polydocanol for the treatment of Epistaxis in HHT: 15 years of experience.</article-title>
                <source>Rhinology.</source>
                <year>2012</year>
                <volume>50</volume>
                <fpage>80</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22469609</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.morgan.2002.e12">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ismail</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mao</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Madan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnes</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudgins</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manning</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Intracranial hemorrhage in infants and children with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome).</article-title>
                <source>Pediatrics.</source>
                <volume>109</volume>
                <fpage>E12</fpage>
                <pub-id pub-id-type="pmid">11773580</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.nawaz.2008.1582">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nawaz</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Litt</surname>
                    <given-names>HI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stavropoulos</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Charagundla</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shlansky-Goldberg</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freiman</surname>
                    <given-names>DB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chittams</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pyeritz</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trerotola</surname>
                    <given-names>SO</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Digital subtraction pulmonary arteriography versus multidetector CT in the detection of pulmonary arteriovenous malformations.</article-title>
                <source>J Vasc Interv Radiol</source>
                <volume>19</volume>
                <fpage>1582</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">18774307</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.olitsky.2012.375">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Olitsky</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <article-title>Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia.</article-title>
                <source>Am J Otolaryngol.</source>
                <year>2012</year>
                <volume>33</volume>
                <fpage>375</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">22079094</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.olivieri.2007.820">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Olivieri</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagella</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Semino</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lanzarini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valacca</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pilotto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scappaticci</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manfredi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buscarini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danesino</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Analysis of ENG and ACVRL1 genes in 137 HHT Italian families identifies 76 different mutations (24 novel). Comparison with other European studies.</article-title>
                <source>J Hum Genet</source>
                <volume>52</volume>
                <fpage>820</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17786384</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.omalley.2012.886">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>O'Malley</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>LaGuardia</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalady</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parambil</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heald</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Church</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burke</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>The prevalence of hereditary hemorrhagic telangiectasia in juvenile polyposis syndrome.</article-title>
                <source>Dis Colon Rectum.</source>
                <year>2012</year>
                <volume>55</volume>
                <fpage>886</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">22810475</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.suppressa.2011.365">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Suppressa</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liso</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabb&#x000e0;</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia.</article-title>
                <source>Br J Haematol.</source>
                <year>2011</year>
                <volume>152</volume>
                <fpage>365</fpage>
                <pub-id pub-id-type="pmid">21265821</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.pece.1997.2568">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pece</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vera</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cymerman</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>RI</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Wrana</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Letarte</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Mutant endoglin in hereditary hemorrhagic telangiectasia type 1 is transiently expressed intracellularly and is not a dominant negative.</article-title>
                <source>J Clin Invest</source>
                <volume>100</volume>
                <fpage>2568</fpage>
                <lpage>79</lpage>
                <pub-id pub-id-type="pmid">9366572</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.plauchu.1989.291">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Chadar&#x000e9;vian</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bideau</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robert</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>1989</year>
                <article-title>Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population.</article-title>
                <source>Am J Med Genet</source>
                <volume>32</volume>
                <fpage>291</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">2729347</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.porteous.1992.527">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Porteous</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burn</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Proctor</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Hereditary haemorrhagic telangiectasia: a clinical analysis.</article-title>
                <source>J Med Genet</source>
                <volume>29</volume>
                <fpage>527</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">1518020</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.prigoda.2006.722">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Prigoda</surname>
                    <given-names>NL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Savas</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdalla</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piovesan</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rushlow</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vandezande</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozcelik</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallie</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Letarte</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Hereditary haemorrhagic telangiectasia: mutation detection, test sensitivity and novel mutations.</article-title>
                <source>J Med Genet</source>
                <volume>43</volume>
                <fpage>722</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16690726</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.proctor.2008.756">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Proctor</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henderson</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dziura</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>RI</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <article-title>Hormonal therapy for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.</article-title>
                <source>J Clin Gastroenterol.</source>
                <year>2008</year>
                <volume>42</volume>
                <fpage>756</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">18496387</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.reh.2013.820">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Reh</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hur</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merlo</surname>
                    <given-names>CA</given-names>
                  </name>
                </person-group>
                <article-title>Efficacy of a topical sesame/rose geranium oil compound in patients with hereditary hemorrhagic telangiectasia associated epistaxis.</article-title>
                <source>Laryngoscope.</source>
                <year>2013</year>
                <volume>123</volume>
                <fpage>820</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">23401038</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.revencu.2013a.1632">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Revencu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boon</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mendola</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cordisco</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dubois</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clapuyt</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hammer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amor</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Irvine</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baselga</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dompmartin</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Syed</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin-Santiago</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ades</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandaradura</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barrio</surname>
                    <given-names>VR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burrows</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blei</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cozzolino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunetti-Pierri</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vicente</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abramowicz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000e9;sir</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilain</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chung</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gardiner</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dwight</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lord</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fishman</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cytrynbaum</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chamlin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghali</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilaberte</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joss</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boente Mdel</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000e9;aut&#x000e9;-Labr&#x000e8;ze</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Delrue</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayliss</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martorell</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gonz&#x000e1;lez-Ense&#x000f1;at</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazereeuw-Hautier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Donnell</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bessis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pyeritz</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salhi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>OT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wargon</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulliken</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vikkula</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>RASA1 mutations and associated phenotypes in 68 families with capillary malformation-arteriovenous malformations.</article-title>
                <source>Hum Mutat</source>
                <year>2013a</year>
                <volume>34</volume>
                <fpage>1632</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">24038909</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.revencu.b">
              <mixed-citation publication-type="book">Revencu N, Boon LM, Vikkula M. Capillary malformation/arteriovenous malformation. In: Rimoin DL, Pyeritz RE, Korf BR, eds. <italic toggle="yes">Emery and Rimoin's Principles and Practice of Medical Genetics</italic>. 6 ed. Chap 57. Academic Press; 2013b.</mixed-citation>
            </ref>
            <ref id="hht.REF.richer.2012.401">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Richer</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geisthoff</surname>
                    <given-names>UW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Livada</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ward</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mainka</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Henderson</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maune</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>RI</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <article-title>The Young's procedure for severe epistaxis from HHT.</article-title>
                <source>Am J Rhinol Allergy.</source>
                <year>2012</year>
                <volume>26</volume>
                <fpage>401</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">23168156</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.richardsyutz.2010.61">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Richards-Yutz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grant</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chao</surname>
                    <given-names>EC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walther</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganguly</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Update on molecular diagnosis of hereditary hemorrhagic telangiectasia.</article-title>
                <source>Hum Genet.</source>
                <year>2010</year>
                <volume>128</volume>
                <fpage>61</fpage>
                <lpage>77</lpage>
                <pub-id pub-id-type="pmid">20414677</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.rigelsky.2008.2551">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rigelsky</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jennings</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehtonen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minai</surname>
                    <given-names>OA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eng</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aldred</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>BMPR2 mutation in a patient with pulmonary arterial hypertension and suspected hereditary hemorrhagic telangiectasia.</article-title>
                <source>Am J Med Genet A</source>
                <volume>146A</volume>
                <fpage>2551</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18792970</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.schulte.2005.595">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schulte</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geisthoff</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lux</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kupka</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zenner</surname>
                    <given-names>HP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pfister</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>High frequency of ENG and ALK1/ACVRL1 mutations in German HHT patients.</article-title>
                <source>Hum Mutat</source>
                <volume>25</volume>
                <fpage>595</fpage>
                <pub-id pub-id-type="pmid">15880681</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.shovlin.2000.66">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shovlin</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guttmacher</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buscarini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faughnan</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westermann</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kjeldsen</surname>
                    <given-names>AD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plauchu</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).</article-title>
                <source>Am J Med Genet</source>
                <volume>91</volume>
                <fpage>66</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10751092</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.soubrier.2013.d13">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Soubrier</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chung</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Machado</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gr&#x000fc;nig</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aldred</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geraci</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loyd</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elliott</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trembath</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newman</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Humbert</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2013</year>
                <article-title>Genetics and Genomics of Pulmonary Arterial Hypertension.</article-title>
                <source>J Am Coll Cardiol.</source>
                <volume>62</volume>
                <fpage>D13</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">24355637</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.thompson.2014.91">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Figueroa-Bodine</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Livada</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richer</surname>
                    <given-names>SL</given-names>
                  </name>
                </person-group>
                <article-title>Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia.</article-title>
                <source>Allergy Rhinol (Providence)</source>
                <year>2014</year>
                <volume>5</volume>
                <fpage>91</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">25199101</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.trerotola.2010.837">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Trerotola</surname>
                    <given-names>SO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pyeritz</surname>
                    <given-names>RE</given-names>
                  </name>
                </person-group>
                <article-title>PAVM embolization: an update.</article-title>
                <source>AJR Am J Roentgenol.</source>
                <year>2010</year>
                <volume>195</volume>
                <fpage>837</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">20858807</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.wain.2014.588">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wain</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ellingson</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gammon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roberts</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pichurin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winship</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riegert-Johnson</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weitzel</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindor</surname>
                    <given-names>NM</given-names>
                  </name>
                </person-group>
                <article-title>Appreciating the broad clinical features of SMAD4 mutation carriers: a multicenter chart review.</article-title>
                <source>Genet Med.</source>
                <year>2014</year>
                <volume>16</volume>
                <fpage>588</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">24525918</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.white.1996.2627">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>RI</given-names>
                    <suffix>Jr</suffix>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia: embolotherapy using balloons and coils.</article-title>
                <source>Arch Intern Med</source>
                <volume>156</volume>
                <fpage>2627</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">8951309</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.whitehead.2016.943">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Whitehead</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sautter</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McWilliams</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chakinala</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merlo</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>James</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Everett</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clancy</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faughnan</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oh</surname>
                    <given-names>SP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olitsky</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pyeritz</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gossage</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <article-title>Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: a randomized clinical trial.</article-title>
                <source>JAMA</source>
                <year>2016</year>
                <volume>316</volume>
                <fpage>943</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">27599329</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.wooderchakdonahue.2013.530">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wooderchak-Donahue</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Fallon</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Upton</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roman</surname>
                    <given-names>BL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plant</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>F&#x000fc;l&#x000f6;p</surname>
                    <given-names>GT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morrell</surname>
                    <given-names>NW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Botella</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernabeu</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevenson</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Runo</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayrak-Toydemir</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <article-title>BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2013</year>
                <volume>93</volume>
                <fpage>530</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23972370</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.yaniv.2009.284">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yaniv</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Preis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadar</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shvero</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haddad</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial.</article-title>
                <source>Laryngoscope</source>
                <year>2009</year>
                <volume>119</volume>
                <fpage>284</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19160429</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="hht.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="hht.Suggested_Reading.reflist0">
            <ref id="hht.REF.aretz.2007.702">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aretz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stienen</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Uhlhaas</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stolte</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Entius</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loff</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Back</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaufmann</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keller</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blaas</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siebert</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogt</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spranger</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holinski-Feder</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunde</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Propping</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedl</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <article-title>High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome.</article-title>
                <source>J Med Genet</source>
                <year>2007</year>
                <volume>44</volume>
                <fpage>702</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17873119</pub-id>
              </element-citation>
            </ref>
            <ref id="hht.REF.marchuk">
              <mixed-citation publication-type="book">Marchuk DA, Lux A. Hereditary hemorrhagic telangiectasia. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID)</italic>. Chap 212. New York, NY: McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="hht.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="hht.Acknowledgments">
          <title>Acknowledgments</title>
          <p>Robert I White, MDSchool of Medicine, Yale University</p>
          <p>Alan Guttmacher, MDNational Human Genome Research Institute, National Institutes of Health</p>
        </sec>
        <sec id="hht.Author_History">
          <title>Author History</title>
          <p>Alan Guttmacher, MD; National Institutes of Health (2000-2009) Jamie McDonald, MS, CGC (2000-present) Reed E Pyeritz, MD, PhD, FACMG (2009-present)</p>
        </sec>
        <sec id="hht.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>2 February 2017 (sw) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>24 July 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>5 January 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>19 May 2009 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>22 November 2005 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>16 March 2004 (cd) Revision: sequence analysis</p>
            </list-item>
            <list-item>
              <p>26 February 2004 (cd) Revision: quantitative PCR added as a test method</p>
            </list-item>
            <list-item>
              <p>4 August 2003 (cd) Revisions</p>
            </list-item>
            <list-item>
              <p>17 June 2003 (ca) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>26 June 2000 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>January 2000 (jm) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
